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CHAPTER I: INTRODUCTION AND BACKGROUND 
Bipolar Disorder 
 Bipolar disorder is a debilitating illness that affects more than 3 million adult 
Americans [1]. People with this disease experience severe fluctuations in mood, from a 
very high-energy, manic state to a low-energy, depressed state. During manic states they 
are known to become impulsive and highly irritable, and experience racing thoughts, 
excessive talkativeness and decreased sleep. Sometimes suddenly they can transition to a 
depressed state with symptoms including increased feelings of hopelessness and sorrow, 
lack of energy, increased sleep, and thoughts of suicide. Indeed, lifetime incidence of 
suicide for bipolar patients is between 10-20% [2]. There are subsets of the disorder, with 
bipolar I consisting of repeated cycles of depressive and manic episodes, and bipolar II 
consisting of depressive and hypomanic episodes [2]. Episodes can last for days, months, 
or even years [1]. Bipolar disorder usually develops in late adolescence and early 
adulthood and without treatment can persist until death. This disorder also has a high rate 
of co-morbidity with alcoholism, leading to further destructive behavior [3]. 
 The mechanisms underlying bipolar disorder are currently unknown. However, 
research has shown that this disorder is correlated with dysregulation in the dopamine 
and serotonin systems, as well as with pathology in the brain systems associated with 
regulating emotions [4]. When there is an excess of dopamine or serotonin, manic 
behavior, such as excessive talkativeness, impulsivity, irritability, and less need for sleep, 
is induced. When there is a deficiency in these amines, depressive mood and behavior, 
such as excessive need for sleep, and feelings of sorrow, helplessness, and worthlessness, 
are induced [1]. Other studies suggest that upregulation of the arachidonic acid (AA) 
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cascade is involved in the development of bipolar disorder. AA is an essential long-chain 
polyunsaturated fatty acid (PUFA), specifically an omega-6 fatty acid, that is involved in 
brain signaling via sertonergic, glutamatergic, dopaminergic, and cholinergic receptor 
stimulation [5]. Upregulation of the AA cascade can induce inflammation and 
neurological dysfunctions which have been implicated in bipolar disorder [6].  
 Drug treatment for bipolar disorder has been employed since the early 1950s with 
the discovery that lithium could stabilize mood [7]. Currently, drugs such as lithium, 
valproate, and carbamazepine are used to treat the symptoms of bipolar disorder. 
Interestingly, it has been shown that these drugs modulate the AA turnover rate in the 
brain. The AA cascade begins with phospholipase A2 (PLA2) hydrolyzing esterified AA 
from membrane phospholipids [5]. Long-chain acyl-CoA synthetases (Acsls) and acyl 
transferase reincorporate a majority of the released AA into brain phospholipids, while 
enzymes such as cyclooxygenases (COX) convert a small amount of the released AA into 
eicosanoids. Using radiolabeled fatty acid and quantitative autoradiographic analysis, 
incorporation rates of plasma unesterified AA into brain phospholipids can be determined 
in rodents [8]. Using these techniques, Chang et al. showed that chronic intake of lithium 
decreased AA turnover within the brain of rats by decreasing brain COX-2 activity and 
inhibiting the transcription of cPLA2, which is the AA-selective calcium-dependent 
cytosolic form of PLA2 [9]. Likewise, carbamazepine also decreases the turnover rate of 
AA in the rodent brain by decreasing COX-2 activity and inhibiting transcription of 
cPLA2 [10]. Valproic acid also decreases the turnover rate of AA in the rodent brain, 
however, it appears to do so by inhibiting Acsl [11] and prevents nuclear factor-κB 
(NFκB) from inducing the transcription of COX-2 [12]. Figure 1, courtesy of Rao et al., 
3 
summarizes the mode of action of lithium, carbamazepine, and valproic acid to affect 
turnover rates of AA [5]. Though there is strong evidence for the modulation of the AA 
cascade, other mechanisms of action for mood stabilizers have been postulated that 
include the involvement of inositol depletion, glycogen synthase kinase-3, protein kinase 
C, mitochondrial dysfunction and neurotrophins to name a few [13]. Mood stabilizing 
medication, though highly effective in reducing the symptoms of bipolar disorder, can 
cause many side effects including gastrointestinal pain, diarrhea, tremor, nocturnal 
urination, weight gain, oedema, flattening of affect, exacerbation of psoriasis, problems 
with memory, vigilance, reaction time and tracking, and have even led to death in some 
patients [14]. Prescription of these drugs for children and adolescents with bipolar 
disorder or who are at high-risk for developing the disorder is controversial, as the risk 
for experiencing adverse side effects is higher for these individuals [15]. In addition, it 
has been shown that mood stabilizing medication can cause birth defects in babies born to 
women on these medications during their pregnancy, and they can be transferred to the 
baby through breast milk [14, 16]. Thus, an alternative approach is needed to help 
stabilize the mood of bipolar patients, especially adolescents and pregnant women, that 
will not cause harm or negative side effects.  
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Figure 1. The arachidonic acid (AA) cascade and how drugs prescribed to fight bipolar 
disorder modulate the cascade. Specifically, lithium, carbamazepine, and valproate were 
shown to attenuate the cascade (Figure from Rao et al., 2008 [5]).  
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Omega-3 Fatty Acids 
 Omega-3 fatty acids, a subset of PUFAs, are essential nutrients that are involved 
in normal brain development and influence behavior and mood [17]. Currently, omega-3 
fatty acid supplements are given to minimize the symptoms of rheumatoid arthritis [18] 
and coronary heart disease [19]. Preclinical trials of omega-3 fatty acid supplements have 
shown benefits for patients with autism, dyslexia, aggression and mood disorders [17]. 
Examples of key omega-3 fatty acids potentially involved in regulating mood include 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Indeed, studies by 
McNamara et al. found that erythrocyte DHA levels were 32% lower in bipolar patients 
compared to age-matched healthy controls [20], and patients with bipolar disorder had 
significant deficits (-24%) in DHA levels in postmortem prefrontal cortex (PFC) as 
compared to normal controls [21]. In addition, a recent study has shown that a diet 
deficient in omega-3 fatty acids is correlated with a heightened risk of developing mood 
disorders, such as bipolar disorder [22]. Omega-3 fatty acids are primarily found in fish 
oils, and interestingly, a study of 12 different countries showed that greater seafood 
consumption predicted lower lifetime prevalence rates of bipolar I disorder, bipolar II 
disorder, and bipolar spectrum disorder [23]. Several preliminary clinical trials have 
reported significant, beneficial results for patients with various psychotic disorders who 
had been given chronic omega-3 fatty acid supplements [24-26]. 
The exact mechanism by which omega-3 fatty acids operate in bipolar patients is 
presently unknown. However, fluctuations in the concentrations and ratios of long-chain 
PUFAs, specifically AA and DHA have been linked to bipolar disorder [5]. As 
mentioned in the previous section, mood stabilizers have been shown to downregulate the 
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AA metabolic cascade in rodents. In these same rodents, the mood stabilizers did not 
affect the DHA cascade [5]. However, when a diet low in omega-3 fatty acids is given to 
rats for 15 weeks, the brain AA metabolic cascade is upregulated, while the DHA cascade 
is downregulated [27]. Increased levels of prostaglandins derived from AA cause 
inflammation and have been linked to neurological diseases. Interestingly, Stahl et al. 
proposed that omega-3 fatty acids reduce the level of these prostaglandins in humans 
[28]. Su argues that the benefit of eating fish with a high amount of EPA and DHA is that 
these fatty acids displace AA from the cell membrane phospholipid pool [6]. As the 
amount of AA turnover is increased in bipolar patients compared to healthy individuals 
[2], this shift may be beneficial for these patients. Piomelli et al. also suggest that DHA 
works by interacting with dopaminergic or sertonergic receptors altered in bipolar patient 
brains to modulate receptor-coupled AA release [29]. Figure 2 summarizes the 
relationship between DHA, EPA and AA and the outcomes of fluctuations of these fatty 
acids (Figure courtesy of Su 2009 [6]). Overall, studies show a connection between 
decreased levels of omega-3 fatty acids in humans and increased rates of bipolar disorder, 
whereas increased levels of these fatty acids in the brain and blood may be beneficial for 
these patients.   
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Figure 2. Genetic and environmental factors related to omega-3 fatty acid and omega-6 
fatty acid involvement in biological processes and dysfunctions. The omega-3 fatty acids 
(DHA and EPA) cause the downregulation of factors that induce neuronal dysfunction, 
whereas the omega-6 fatty acid, arachidonic acid (AA), appears to induce inflammation 
and neuronal dysfunction (Figure from Su 2009 [6]). 
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Previous Studies 
 Our lab had previously identified the D-box Binding Protein (DBP) as a potential 
candidate gene for inducing bipolar disorder [30-31] using Convergent Functional 
Genomics (CFG), which cross-matches various lines of evidence from published 
scientific literature to determine potential candidate genes for psychiatric disorders [30, 
32-34]. This method is described in more detail in the following section. DBP is a 
circadian clock gene that has been mapped on chromosome 19q13 near a human genetic 
linkage locus for depression [35] and bipolar disorder [36]. Circadian clock genes have 
been associated with bipolar disorder, specifically the switch from depression to manic 
states [30, 37-38]. This association is particularly observed as sleep abnormalities, as 
bipolar patients will often feel a need for excessive sleep during their depressed phase, 
but then experience a reduction in need for sleep during the manic stage [39]. Indeed, 
sleep deprivation is often suggested as an initial treatment of severe depression, whereas, 
it can lead to an accelerated switch to a manic episode in patients with bipolar disorder 
[40-41]. Franken et al. found that DBP knockout (KO) mice have abnormal circadian 
rhythms as well as abnormal sleep regulation [42]. To further study the potential role of 
DBP in bipolar disorder and related disorders, our laboratory conducted analyses of 
behavior and gene expression in mice with a constitutive homozygous deletion of DBP 
(DBP KO mice) [31]. Blood and brain gene expression studies were conducted to identify 
genes that change concurrently, and subsequently may provide candidate biomarkers for 
the disease [43]. 
 Similar to sleep deprivation, stress can be the catalyst to induce a switch to a 
manic episode in bipolar patients [40]. For this reason, in our previous study DBP KO 
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and WT mice were stressed for a period of 4 weeks and the outcomes of the open-field 
locomotion test were compared to non-stressed DBP KO and WT mice. To induce 
chronic stress, mice were single-housed and underwent a stress paradigm consisting of 
forced swim, tail flick, and tail suspension test to induce acute stress. The day prior to the 
stress paradigm, the mice were also sleep deprived by keeping lights off (as mice are 
nocturnal) for a complete 24 hours, as sleep deprivation in humans can cause depression 
symptoms in healthy adults and enhance the switch to manic states in bipolar patients 
[40]. A week after the stress paradigm, the open-field test was administered to track 
movement.  
The open-field test is used to measure exploratory behavior and locomotor 
activity in rodents. Using this technique, one can discover motor deficits and anxiety-
related behavior. The open field is typically a square enclosure with high walls to prevent 
escape. This box is divided into nine regions: four corners, four side squares, and one 
center square. A video camera is placed above the box to capture images that are 
analyzed with computer software to determine the amount of time the rodent spends in 
motion or resting, the velocity of movement, and the region in which the rodent is 
moving after it is placed in the square enclosure. Visual tracking files of the rodent 
movement are also saved for each trial, with a trial lasting for 30 min in our studies. This 
test can be used to measure anxiety or impulsivity by comparing the amount of time spent 
in the center for a test rodent compared to control. Rodents instinctively spend little time 
in the center region as they are more prone to attack out in the open. Mice or rats that 
spend significantly more time in the center than control may be more impulsive, whereas 
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rodents that spend significantly less time in the center and move less in general than 
control may be more anxious [31].  
In our previous study, non-stressed mice were group housed, did not undergo the 
stress paradigm, and were not sleep deprived. Total distance traveled was determined and 
non-stressed wild-type mice (NST WT), non-stressed DBP KO mice (NST KO), stressed 
wild-type mice (ST WT), and stressed DBP KO mice (ST KO) were compared. At 
baseline, NST KO mice exhibited an overall decrease in the total distance traveled as 
compared to NST WT mice. This effect was reversed with treatment of the stimulant, 
methamphetamine, which has been used in rodent studies to model mania [44]. The 
observed significant decrease in baseline locomotion of NST KO mice compared to NST 
WT mice, along with the reported sleep EEG abnormalities in these KO mice [42], 
suggests that the NST DBP KO mice phenotypically resemble the depressive phase of 
bipolar disorder.  
 When DBP KO mice were subjected to chronic and acute stress they showed a 
diametric switch in their locomotion compared to ST WT mice. ST KO mice were 
hyperlocomotive, while ST WT mice were hypolocomotive (Figure 3a and b), and this 
difference was minimized with administration of methamphetamine (Figure 3a). This 
switch in locomotion resembles the switch from a depressed episode to a manic stage 
when bipolar patients endure stress and/or sleep deprivation [40, 45].  
 If the change in locomotion seen in NST KO mice compared to sleep deprived ST 
KO mice was related to an endophenotype that is related to bipolar disorder, then pre-
treatment of a mood stabilizer should adjust this behavioral response. Indeed, sleep 
deprivation induced a significant increase in locomotion for DBP KO mice, and pre-
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treatment with valproate prior to testing brought this elevated locomotion level back to 
non-sleep deprived levels (Figure 3c). 
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Figure 3. Phenomics of DBP KO ST mice: locomotion, switch, sleep deprivation, 
clustering. (a) Results of open-field test in both wild-type and knockout mice with and 
without methamphetamine treatment (*p-value = 0.037); (b) stress-induced switch in 
total distance traveled (*p-value = 0.016); (c) sleep deprivation caused an increase in the 
total distance traveled by DBP KO mice that was modulated with valproic acid 
pretreatment. SD – sleep deprived, NSD – non-sleep deprived, VPA – valproic acid (*p-
value = 0.007); (d) group, and (e) individual mice clustering of ST – stressed mice and 
NST – non-stressed mice. V. max – maximal velocity, V. mean – mean velocity, red – 
increased, blue – decreased (Figure from Le-Niculescu et al., 2008 [31]). 
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To further show the extremes of behavior between the ST KO and NST KO mice, 
a two-way hierarchical clustering of the mouse locomotor behavioral data measures 
(phenes; Figure 3d,e) [46] was created using GeneSpring. Z scores were determined 
using results from each mouse for the different phenes and were put into the program 
instead of the usual use of gene expression intensity numbers, allowing for the visual 
clustering of phenes. The figure shows that the mice in each group clustered for the most 
part into two distinct groups. A point of interest from this clustering analysis is the 
contrast between ST and NST KOs in the amount of time spent in the center square, 
“Center Time.” ST DBP KO mice spent more time in the center of the field than their 
NST counterparts. This may indicate an increase in risk-taking, impulsive behavior, 
which is often observed in bipolar patients in the manic phase [47]. The phene with the 
strongest contrast between groups is Resting Time. ST KO mice took much less time to 
rest than NST KO mice, which is analogous to increased activity during the manic stage 
of bipolar disorder compared to the decreased activity during the depressed stage. 
 As previously mentioned, there is a high degree of co-morbidity of alcoholism 
with bipolar disorder [3, 48]. For this reason, along with the fact that DBP was identified 
as a potential candidate gene for alcoholism using the CFG approach [34], our lab studied 
the amount of alcohol consumption by male and female DBP KO mice. It was 
hypothesized that alcohol intake would be increased in DBP KO mice, specifically ST 
KO mice, as they may have an increased hedonic impulse to drink more alcohol than ST 
WT counterparts. Interestingly, at baseline during the beginning of the chronic stress 
paradigm (single-housing), ST KO mice drank less alcohol than ST WT mice, however, 
they exhibited a switch in response to the stress and consumed more alcohol over a 30-
14 
day period compared to ST WT mice (Figure 4). With these promising results, along with 
interesting genetic expression studies described in Le-Niculescu et al., 2008 [31], we 
decided to perform further tests on DBP KO mice, as a potential model of bipolar 
disorder. 
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Figure 4. Ethanol consumption during the stress paradigm in DBP KO and WT mice. 
Dotted vertical line indicates acute stress paradigm was performed on that day; * 
indicates p-value < 0.05 (Figure from Le-Niculescu et al., 2008 [31]). 
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Background of Present Study 
 In the following manuscript we used several behavioral and bioinformatic 
techniques to evaluate the differences between the mice in our study. Specifically, the 
forced swim test, open-field video tracking test, microarrays, and the CFG approach were 
used to evaluate behavior in the mice and analyze the genetic information obtained from 
their brains and blood. A brief synopsis of the reasons these specific tests were employed, 
including their potential benefits and limitations, follows. 
Presently, bipolar disorder patients are diagnosed by describing their mood, 
habits, and feelings to a psychiatrist. Since one cannot interview a rodent to determine 
their mood, behavioral tests, which reveal differences in behavior as a result of the 
changes in mood, are necessary. The forced swim test has been implemented since the 
1970s as a way to determine learned helplessness or behavioral despair in rodents and to 
test the effects of antidepressants on reversing this behavior [49]. In their studies on 
memory, Porsolt et al. noticed that in the water maze memory test some of their rodents 
would give up and simply float instead of looking for the exit, leading the researchers to 
propose that these rodents might have been displaying signs of despair. To test this, 
Porsolt dropped mice into a cylinder filled with water for six minutes and immobility was 
recorded for the last four minutes. The group tested the effects of antidepressants on mice 
using this method and found that mice on antidepressants were more mobile than the 
mice without the drugs, allowing them to conclude that this test could provide a measure 
of depression in rodents. In the intervening time, this model, with some modifications, 
has been employed in numerous studies to evaluate the effectiveness of potential 
antidepressants and decipher behavioral differences between wild-type and knockout 
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mice [50]. A potential flaw of this test is that the immobility seen in mice may not be 
representative of depressed mood, but could instead be an attempt of the mouse to 
conserve energy in an inescapable situation. Thus, immobility could be considered an 
adaptive behavior, which could represent successful coping skills, instead of behavioral 
despair [50]. Also, the outcome of this test is reliant on the scoring ability of the observer. 
This can lead to discrepancies between scores for different laboratories. For these 
reasons, this test should not be the only measure of behavioral depression employed in 
rodents. Instead, forced swim can provide preliminary evidence of differences between 
different genetic or treatment groups, and researchers should include other behavioral and 
biochemical tests to validate the observed outcomes. For this reason, we also employed 
the open-field test to measure locomotion and impulsivity in our mice, and gene 
expression studies to examine the genetic differences between our mice.  
The standard protocol for the open-field test was described in detail in the 
previous section. For this test, the most used outcome measure is locomotion, however, 
this outcome can be affected by motor output, exploratory drive, fear-related behavior, 
illness, circadian cycle, and many other factors [51]. Because of this, researchers must 
supplement this test with other analyses to make conclusions about the outcomes. For this 
reason, we employed genetic studies to determine differences among different treatment 
and genetic groups.  
 To determine the up or downregulation of the genes between groups, we removed 
and sectioned the brain, took blood samples, and tested mRNA expression in the blood 
and PFC using the Affymetrix GeneChip Mouse Genome 430 2.0 Array and analyzed 
hybridization using Affymetrix Microarray software. Microarrays were first developed in 
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the late 1990s and are used to detect gene expression levels in cells or tissue by 
measuring the hybridization of mRNA from the samples to tens of thousands of known 
genes that have been attached to a glass surface [52]. Outputs of changes from 
microarrays can be tens of thousands of genes; for this reason, we used a p-value 
threshold of 0.0025 to reduce the output list and to select the most significantly changed 
genes from the list.  
Microarrays have their limitations. For example, mRNA can be degraded and lead 
to false data if tissue has not been processed rapidly. Likewise, tissue samples are a 
mixture of different cell types thus leading to the possibility of a depression of signal-to-
noise as upregulated genetic material in one cell type may be downregulated in other cell 
types [53]. For these reasons, we flash froze brain tissue and preserved the blood samples 
in PAXgene blood RNA collection tubes to prevent mRNA degradation, and we sliced 
the brains into regions, using only the PFC region for microarray analysis. A limitation of 
our approach is that microarrays were our only method for detecting gene expression 
changes thus were possibly accompanied by biological or technical errors, as our 
experiments and microarray analysis require many steps [31, 53]. Knowing this, we 
designed our study to minimize false positives by comparing gene expression data using 
compiled total RNA extracted from the brain tissue samples or blood from three mice per 
treatment and genetic group from experiments performed at three different times. We 
only evaluated the genes that were reproducibly changed in the same direction in at least 
six out of nine independent comparisons. This way, we could be more confident of the 
genes that were shown to be significantly different between groups. Although we used 
methods to reduce the number of genes on the original output list, the number of genes on 
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the remaining list can be quite extensive. For this reason we employed the CFG approach 
to prioritize the list of genes.  
 CFG is an approach that prioritizes the hundreds to thousands of genes that are 
shown to be significantly changed between groups in microarrays [54]. Using multiple 
lines of published evidence for a disease and related diseases, the genes are ranked 
according to their score based on the number of different lines of evidence in which they 
have been associated to the disease. The lines of evidence for this study include human 
genetic linkage or association evidence, human postmortem brain evidence, human blood 
evidence, and mouse genetic evidence, either Quantitative Trait Loci (QTL) or transgenic 
(TG). Once the genes are ranked based on the CFG score, we organize the genes into a 
pyramid as a visual representation of the scoring of the genes and the lines of evidence 
with which they are affiliated, with the highest ranking genes at the top. By cross-
matching multiple lines of independent evidence, more confidence can be placed on the 
gene and its role in the disease, leading to determination of higher probability candidate 
genes, blood biomarkers and potential mechanisms and pathways for the disease. This 
approach has its limitations, as it is reliant on published data, and key genes that have yet 
to be linked to the disease may receive an artificially low score or go unnoticed 
altogether. In this regard, CFG will progress in its accuracy as significant and thorough 
published scientific research progresses. Our hope is that CFG will only get better at 
determining candidate genes and biomarkers with time and the progression of the field.  
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Introduction 
We have previously identified the clock gene D-box Binding Protein (DBP) as a 
potential candidate gene for bipolar disorder [54], alcoholism [34], and schizophrenia 
[55] using a Convergent Functional Genomics (CFG) approach. In follow-up work [31], 
we reported that mice with a homozygous deletion of DBP have lower locomotor 
activity, blunted responses to stimulants, and gain less weight over time. In response to a 
chronic stress paradigm, the mice exhibit a diametric switch in these phenotypes. DBP 
knockout (DBP KO) mice are also activated by sleep deprivation, similar to bipolar 
patients, and that activation is prevented by treatment with the mood stabilizer drug 
valproate. Moreover, these mice show increased alcohol intake following exposure to 
stress. Microarray studies of brain and blood revealed patterns of gene expression 
changes that may explain the observed phenotypes. CFG analysis of the gene expression 
changes identified a series of novel candidate genes and blood biomarkers for bipolar 
disorder, alcoholism and stress reactivity.  
Omega-3 fatty acids (eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA)) are essential fatty acids, DHA being the final metabolic pathway compound. 
They have been described to have mood and psychosis modulating properties, in both 
preclinical models and some clinical trials. For example, deficits in omega-3 fatty acids 
have been linked to increased depression and aggression in animal models [56] and 
humans [57]. Of note, deficits in DHA have been reported in the postmortem 
orbitofrontal cortex of patients with bipolar disorder, and were greater in those that had 
high verses low alcohol abuse [21]. Omega-3 fatty acids have been reported to be 
clinically useful in the treatment of both mood [58-61] and psychotic disorders [62-64]. 
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To date, there is no clear understanding of how omega-3 fatty acids work in terms of 
psychotropic effects, or indeed how effective they are. Unlike most psychiatric drugs, 
these natural compounds have minimal side-effects, and intriguing evidence for favorable 
health benefits [65]. Particularly for female patients of child-bearing age, the potential 
fetus-harming side-effects of mood stabilizing and antidepressant medications are a major 
issue. As such, if the action of omega-3 fatty acids in mood disorders and related 
disorders could be substantiated by understanding their mechanistic effects, they might 
become an important addition to the therapeutic armamentarium of psychiatrists and 
primary care doctors.  
Based on the above, we decided to test omega-3 fatty acids, specifically DHA, as 
a way of reversing the phenotypic, gene expression and biomarker abnormalities present 
in this new model (DBP KO mice). We also studied the effects of DHA on modulating 
alcohol consumption in DBP mice and in an independent animal model, the alcohol-
preferring (P) rat, a well established model of alcoholism. The work described has 
important translational implications for understanding and validating a new treatment 
approach, that follows the Hippocratic principle of “first do no harm” and may favorably 
impact multiple co-morbid conditions.  
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Materials and Methods 
Mouse Colony  
The generation of transgenic mice carrying the DBP KO has been previously 
described in detail [31]. DBP (+/-) heterozygous (HET) mice were bred to obtain mixed 
littermate cohorts of DBP (+/+) wild-type (WT), HET and DBP (-/-) knockout (KO) 
mice. Mouse pups were weaned at 21 days and housed by gender in groups of two to four 
in a temperature- and light-controlled colony on reverse cycle, with food and water 
available ad libitum. DNA for genotyping was extracted by tail digestion with a Qiagen 
DNeasy Tissue kit, following the manufacturer’s protocol for animal tissue (Qiagen, 
Valencia, CA). The following three primers were used for genotyping by polymerase 
chain reaction (PCR):  
Dbp forward: TTCTTTGGGCTTGCTGTTTCCCTGCAGA 
Dbp reverse: GCAAAGCTCCTTTCTTTGCGAGAAGTGC (WT allele) 
lacZ reverse: GTGCTGCAAGGCGATTAAGTTGGGTAAC (KO allele) 
WT or KO mice 8 to 12 weeks old were used for experiments.  
Animal Housing, Diets and Treatment 
All mice were housed for at least one week prior to each experiment in a room set 
to an alternating light cycle with 12 hours of darkness from 10 a.m. to 10 p.m., and 12 
hours of light from 10 p.m. to 10 a.m. At the start of the experiment, male and female 
DBP WT, or DBP KO mice were placed one of two diets: (1) low DHA custom research 
diet (TD. 00522 Harlan Teklad, Madison, WI), a DHA-depleted low omega-3 PUFA test 
diet adequate in all other nutrients (n-6/n-3 ratio of 85:1 with 6% fat as safflower oil) [66]; 
or (2) high DHA custom research diet (TD. 07708 same as the low DHA diet, except 
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supplemented with 0.69% Algal DHA; Martek Bioscience, Columbia, MD) [66]. The 
DBP mice were fed the low DHA diet (0% DHA), or high DHA diet (0.69% DHA) for 
28 days. Mice, food, and water were weighed twice a week. Water was refilled once a 
week.  
During the 28 day period, the mice were single-housed to induce chronic stress, 
and underwent behavioral challenge tests on day 21 of the experiment to induce acute 
stress. The behavioral challenge tests consisted of sequential administration of the forced 
swim test, tail flick test, and tail suspension test. At four weeks (day 28) the mice were 
injected with saline to keep handling consistent with previous work [31] and open-field 
locomotor activity was assessed with SMART II video-tracking software. After video-
tracking, brain and blood were harvested as previously described [31] for use in 
microarray studies. 
Behavioral Challenge Tests 
Forced Swim Test 
Forced swim test (FST) experiments were performed on day 21 of treatment 
during the dark cycle. Mice were placed in a transparent Plexiglas cylinder (64 cm height 
x 38 cm diameter), with water depth of 30 cm and temperature of 23±2°C. Water was 
replaced after each mouse. Time spent immobile in a 10 minute interval was scored live 
by two independent observers blinded to the animal’s genotype and treatment group.  
Tail Flick 
Immediately following the FST, the mice were dried with paper towels and placed 
in the Plexiglas chamber of the Tail Flick Analgesia Meter System (San Diego 
Instruments, San Diego, CA). The mouse’s tail was placed over a window located on the 
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Tail Flick platform where a light beam shines to heat the tail at a reliable, reproducible 
rate for 20±1 sec. This test was performed as an acute stressor, and not as a way to 
measure the mouse’s response to pain, as it is confounded by the preceding FST. 
Tail suspension 
For the third part of the acute stress paradigm, the mouse was suspended by its 
tail, approximately 30 cm above the ground for 5 minutes. This test was also performed 
as an acute stressor, and not as a way to measure the mouse’s behavior, as it is 
confounded by the preceding tests. 
Locomotion Pattern Testing 
A SMART II Video Tracker system (San Diego Instruments, San Diego, CA) 
under normal light was used to track movement of mice. The mice were placed in the 
lower-right-hand corner of one of four adjacent, 41x41x34 cm3 enclosures. Mice were not 
allowed any physical contact with other mice during testing. Each enclosure had nine pre-
defined areas, that is, center area, corner area, and wall area. The movements of the mice 
were recorded for 30 minutes. The enclosures were cleaned with ethanol and water after 
each tracking. Measures of total distance traveled, center entry, center time, fast 
movement, resting time, average velocity (V mean) and maximum velocity (V max) were 
obtained. 
Alcohol Consumption Experiments in DBP KO Mice 
To create an alcohol free-choice drinking paradigm, male WT and DBP KO mice 
were placed in individual cages with both a bottle of ~250 ml cold tap water and a bottle 
of ~250 ml 10% v/v ethanol, and either the low or high DHA diet for 28 days, with an 
acute stressor (behavioral challenge tests described above) on day 21. The amount of 
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ethanol and water consumed was recorded twice a week, at which time the location of the 
bottles was switched to prevent positional bias. The bottles were refilled with fresh 
solution once a week. Following 28 days of free-choice drinking, the animals were 
injected with saline and their locomotor activity was assessed with SMART II video-
tracking software. After video-tracking, the microsurgery was performed to separate 
brain into regions and blood of each animal was harvested for use in future microarray 
studies. 
Alcohol Consumption Experiments in Alcohol-Preferring (P) rats  
Experimentally naïve, male alcohol-preferring (P) rats, 4-6 months of age at the 
start of the experiment, were used as subjects. They were placed on three diets: (1) low 
DHA custom research diet (described above); (2) high DHA custom research diet 
(described above); and (3) normal rat chow (7001 Harlan Teklad, Madison, WI) for a 
duration of 28 days. Food and water were available ad libitum throughout the 
experiments. Rats were given continuous free-choice access in the home cage to 15% v/v 
ethanol and water. Alcohol intake was measured daily throughout the experiment.  
Behavioral Statistical Analysis 
 Behavioral data are expressed as the mean and ± S.E.M. Two-way analysis of 
variance (ANOVA) was used to determine statistically significant differences for factors 
of gender, genotype, and diet, using SPSS statistical software (SPSS Inc., Chicago, IL). It 
was determined a priori based on previous research to use one-tailed, two sample 
independent t-tests assuming unequal variance to determine significant differences 
between individual groups. Differences between groups were considered significant at p 
≤ 0.05.  
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RNA Extraction and Microarray Work 
Following the open-field locomotor test, mice were sacrificed by cervical 
dislocation, decapitated and brains and blood were harvested. Behavioral testing and 
tissue harvesting were done at the same time of day in all experiments. Once the brains of 
the mice were harvested, they were stereotactically sliced, and hand micro-dissected 
using Paxinos mouse anatomical atlas coordinates, to isolate anatomical regions of 
interest [32, 55]. Tissues were flash frozen in liquid nitrogen and stored at -80°C pending 
RNA extraction. Approximately 0.5-1.0 ml of blood per mouse was collected into a 
PAXgene blood RNA collection tubes (BD diagnostic; www.VWR.com). The PAXgene 
blood vials were stored at -4°C overnight, and then at -80°C until future processing for 
RNA extraction. 
Standard techniques were used to obtain total RNA (22 gauge syringe 
homogenization in RLT buffer) and to purify the RNA (RNeasy mini kit, Qiagen, 
Valencia, CA) from micro-dissected mouse brain regions. For the whole mouse blood 
RNA extraction the PAXgene blood RNA extraction kit (PreAnalytiX, a Qiagen/BD 
company) was used, followed by GLOBINclear™–Mouse/Rat (Ambion/Applied 
Biosystems Inc., Austin, TX) to remove the globin mRNA. All the methods and 
procedures were carried out as per the manufacturer’s instructions. The quality of the 
total RNA was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo 
Alto, CA). The quantity and quality of total RNA was also independently assessed by 260 
nm UV absorption and by 260/280 ratios, respectively (Nanodrop spectrophotometer). 
Starting material of total RNA labeling reactions was kept consistent within each 
independent microarray experiment. 
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Equal amounts of total RNA extracted from the PFC brain tissue samples or blood 
from 3 mice per group was pooled for each experimental condition and used for labeling 
and hybridization to Mouse Genome 430 2.0 arrays (Affymetrix, Santa Clara, CA). The 
GeneChip Mouse Genome 430 2.0 Array contains over 45,000 probe sets that analyze the 
expression level of over 39,000 transcripts and variants from over 34,000 well-
characterized mouse genes. Standard Affymetrix protocols were used to reverse 
transcribe the messenger RNA and generate biotinlylate cRNA 
(http://www.affymetrix.com). The amount of cRNA used to prepare the hybridization 
cocktail was kept constant within each experiment. Samples were hybridized at 45ºC for 
17 hours under constant rotation. Arrays were washed and stained using the Affymetrix 
Fluidics Station 400 and scanned using the Affymetrix Model 3000 Scanner controlled by 
GCOS software. All sample labeling, hybridization, staining and scanning procedures 
were carried out as per the manufacturer’s recommendations.  
Quality Control  
All arrays were scaled to a target intensity of 1000 using Affymetrix MASv 5.0 
array analysis software. Quality control measures including 3’/5’ ratios for GAPDH and 
beta-actin, scaling factors, background, and Q values were used. 
Microarray Data Analysis 
Data analysis was performed using Affymetrix Microarray Suite 5.0 software 
(MAS v5.0). Default settings were used to define transcripts as present (P), marginal (M), 
or absent (A). A comparison analysis was performed for DBP KO mice on the high DHA 
diet, using DBP KO mice on low DHA diet mice as the baseline. “Signal,” “Detection,” 
“Signal Log Ratio,” “Change,” and “Change p-value,” were obtained from this analysis. 
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An empirical p-value threshold for change of p<0.0025 was used. Only transcripts that 
were reproducibly changed in the same direction in two out of three comparisons were 
analyzed further.  
Gene Identification 
The identities of transcripts were established using NetAFFX (Affymetrix, Santa 
Clara, CA), and confirmed by cross-checking the target mRNA sequences that had been 
used for probe design in the Affymetrix Mouse Genome 430 2.0 arrays GeneChip® with 
the GenBank database. Where possible, identities of ESTs are established by BLAST 
searches of the nucleotide database. A National Center for Biotechnology Information 
(NCBI) (Bethesda, MD) BLAST analysis of the accession number of each probe-set was 
performed to identify each gene name. BLAST analysis identifies the closest known 
mouse gene existing in the database (the highest known mouse gene at the top of the 
BLAST list of homologues) which then could be used to search the GeneCards database 
(Weizmann Institute, Rehovot, Israel) to identify the human homologue. Probe-sets that 
did not have a known gene are labeled “EST” and their accession numbers kept as 
identifiers.  
Human Tissue (Postmortem Brain, Blood) Convergence 
Information about our candidate genes was obtained using GeneCards, the Online 
Mendelian Inheritance of Man database 
(http://ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM), as well as database searches using 
PubMed (http://ncbi.nlm.nih.gov/PubMed) and various combinations of keywords (gene 
name, bipolar, depression, alcoholism, stress, anxiety). 
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Human Genetic (Linkage, Association) Convergence 
To designate convergence for a particular gene, the gene had to map within 10 cM 
(see [54] for detailed discussion) of a microsatellite marker for which at least one 
published study showed evidence of genetic linkage or a positive association study for 
the gene itself (for bipolar disorder, depression, alcoholism, stress, anxiety). The 
University of Southampton’s sequence-based integrated map of the human genome (The 
Genetic Epidemiological Group, Human Genetics Division, University of Southampton: 
http://cedar.genetics.soton.ac.uk/public_html/) was used to obtain cM locations for both 
genes and markers. The sex-averaged cM value was calculated and used to determine 
convergence to a particular marker. For markers that were not present in the Southampton 
database, the Marshfield database (Center for Medical Genetics, Marshfield, WI, USA: 
http://research.marshfieldclinic.org/genetics) was used with the NCBI Map Viewer 
website to evaluate linkage convergence. We have established in the laboratory manually 
created databases of all the published human postmortem and human genetic literature to 
date on bipolar and related disorders. These large databases have been used in our CFG 
cross-validation analyses. 
Mouse Genetic (QTL, transgenic) Convergence 
To search for mouse genetic evidence – QTL (Quantitative Trait Loci) or 
transgenic (TG) – for our candidate genes, we utilized MGI_3.54 - Mouse Genome 
Informatics (Jackson Laboratory) and used the search menu for mouse phenotypes and 
mouse models of human disease/abnormal behaviors, using the following sub-categories: 
abnormal emotion/affect behavior, abnormal sleep pattern/circadian rhythm, addiction 
and drug abuse. To designate convergence for a particular gene, the gene had to map 
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within 10 cM of a QTL marker for the abnormal behavior, or a transgenic mouse of the 
gene itself displayed that behavior.  
CFG Analysis Scoring  
Genes that changed in the same direction in two out of three experiments in the 
brain or blood of DBP KO mice on the high DHA diet compared to mice on the low 
DHA diet were scored. Genes changed in the PFC received 1 point; genes changed in the 
blood received an additional 1 point. If the brain and blood direction of change was 
concordant, the gene received an additional 2 points. The other four cross-validating lines 
of evidence (human and animal model data) received a maximum of 1 point each (for 
human genetic data: 0.5 points if it was linkage, 1 point if it was association; for mouse 
genetic data: 0.5 points if it was QTL, 1 point if it was transgenic). Thus, the maximum 
possible CFG score for each gene was 8 points.  
As we are interested in discovering brain-blood candidate biomarker genes of 
response to DHA, we weighted data from the DHA treated DBP KO ST mice more 
heavily, bringing the data from this one methodological approach on par with the data 
from all the other methodological approaches combined. It has not escaped our attention 
that other ways of weighing the scores of line of evidence may give slightly different 
results in terms of prioritization, if not in terms of the list of genes per se. Nevertheless, 
we feel this simple scoring system provides a good separation of genes based on our 
focus on identifying candidate genes for mood. 
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Pathway Analysis  
Ingenuity 8.0 (Ingenuity Systems, Redwood City, CA) was employed to analyze 
the molecular networks, biological functions and canonical pathways of the top candidate 
genes resulting from our CFG analysis. The list of top genes was entered into the 
software and charts were made based on the provided results.  
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Results 
Phenomic Studies: Behavioral Effects of DHA in DBP KO mice 
In order to see the effects of dietary omega-3 fatty acid supplementation on our 
animal model, we tested the effects of a diet high in the omega-3 fatty acid, DHA, verses 
a diet low in DHA. We used a diet enriched in DHA, as the evidence for efficacy of EPA, 
the other main omega-3 fatty acid, is less encouraging [67]. Overall results for the forced 
swim test did not reach significance using two-way ANOVA (Figure 5a), however 
significance was reach for females when separating the mice based on gender (Figure 5c. 
Two-factor ANOVA p-value = 0.02). There was a significant difference in immobility 
time between ST WT and ST KO mice on low DHA diet (t-test p-value = 0.002), with ST 
WT mice swimming significantly less than ST KO mice. However, this significant gap 
between immobility times was reduced for female mice on the high DHA diet, as there 
was no longer a significant difference between ST WT and ST KO on this diet (t-test p-
value=0.32). There was also a significant difference between ST WT mice on the high 
DHA diet compared to WT littermates on the low DHA diet (t-test, p-value = 0.02). 
There was a trend toward decreased swimming for ST KO mice on the high DHA diet 
compared to ST KO mice on the low DHA diet (t-test p-value = 0.09). Weight gain was 
not significantly different among groups (ANOVA p-value = 0.50, data not shown). 
Although males did not show a significant difference among groups in the forced 
swim test, there were trends similar to that of female forced swim data (Figure 5e. 
ANOVA p-value = 0.62). Open-field video tracking revealed similar results regarding 
mobility to that of female forced swim data (Figure 5f. ANOVA p-value = 0.05). There 
was a significant difference in total distance traveled between ST WT and ST KO on the 
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low DHA diet (t-test p-value = 0.0002), with ST WT mice moving significantly less than 
ST KO mice. However, there was no significant difference in immobility time between 
ST WT and ST KO male mice on the diet high in DHA (t-test p-value = 0.08). 
Significance was also reached for the difference between ST KO mice on the high DHA 
diet compared to KO littermates on the low DHA diet (t-test p-value = 0.03). Weight gain 
was not significantly different among groups (ANOVA p-value = 0.77, data not shown). 
Female mice showed similar trends to males during video tracking, but did not reach 
statistical significance (Figure 5d. ANOVA p-value = 0.16). 
Similar to our previous results for male ST DBP KO verses NST DBP KO male 
mice [31], the measure of resting time in the open-field test was most different between 
male ST KO mice on high (increased) verses low (decreased) DHA diet (data not shown). 
Likewise, center time (time spent in the center region of the open field), was decreased in 
mice on the high diet verses low DHA diet. A decrease in center time may correlate with 
a decrease in risk-taking behavior, as mice generally avoid the potentially dangerous, 
center area of an open field. 
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Figure 5. Effects of DHA on ST DBP KO and ST WT mice behavior. DBP mice on a diet 
supplemented with low or high DHA were subjected to a chronic stress paradigm 
consisting of isolation (single housing) for 4 weeks, with an acute stressor (behavioral 
challenge tests) at day 21. Panels a, c, and e show forced swim test results. After 21 days 
of the stress paradigm, the forced swim test was used to measure immobility during a 10 
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min period. Panels b, d and f show open-field video tracking results. After the 28 day 
stress paradigm, the open-field test was used to measure total distance traveled (in 
centimeters) during a 30 min period. Two-factor ANOVA testing Genotype and Diet was 
employed. * indicates t-test p-value ≤ 0.05 
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DHA-Induced Changes in Gene Expression Patterns 
 For our gene expression studies based on microarray data, the CFG approach was 
used (Figure 6) and the scoring process was described in the Material and Methods 
section. With a minimum CFG cut-off score of 2.0 points, we were able to generate a list 
of 72 genes for females and 40 genes for males that were changed with a p-value 
threshold for change of p<0.0025 in at least two out of three microarray experiments 
comparing ST DBP KO mice on a high verses low DHA diet (Tables 1 and 2). Among 
the genes changed by DHA treatment in female mice were CD44, MBP, DRD2, ERBB3, 
GSN, MAL, MAG, NEFH, ESR1, SYT2, CNP, MOG, CLDN11, QDPR, PTN, CRYAB, 
KIF5C, CSRP1, ST18, APOD, SYN2, GPR37, PRDX2, MOBP, PLP1, and PDE8A. 
These genes were changed in the opposite direction in the PFC of the ST KO mice on the 
high DHA diet as compared to the postmortem brain or blood of humans with bipolar 
disorder, alcoholism, anxiety disorders, or major depression (Table 1). According to CFG 
of microarray data for male ST DBP KO mice on the high verses low DHA diet, SFPQ, 
ATRX, ARF3, NDUFAB, FOS, ADAR, MAX, TXNDC13, UBE2D2, COL16A1, and 
TIMM9 were changed in the opposite direction in the PFC of the male ST KO mice on 
the high DHA diet as compared to the postmortem brain or blood of humans with bipolar 
disorder, alcoholism, anxiety disorders, or major depression (Table 2). 
 Based on the CFG tables, pyramids were made providing the top candidate genes 
(3.0 points and higher) changed in female and male ST KO mice on the high verses low 
DHA diet, with the genes receiving the highest CFG score placed at the top (Figure 7, A 
and B). The genes are also designated by the line of evidence for which they were 
reported. Based on these findings, genes serving as potential biomarkers for monitoring 
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of DHA treatment in ST DBP KO mice include CD44, EFHD1, and TFRC, as they were 
changed in the same direction in the brain and blood of ST DBP KO mice. 
Overlap with Previous Findings 
 Previous microarray and CFG data on ST DBP KO mice PFC brain regions 
compared to WT mice PFC brain regions revealed a list of top candidate genes for 
bipolar disorder and stress response [31]. In that study, ADP-ribosylation factor 3 (Arf3) 
was decreased in the PFC of male ST KO mice compared to WT control. In the present 
study, Arf3 was increased in the PFC of male ST KO mice on a high DHA diet compared 
to their male counterparts on a low DHA diet, showing the potential role of omega-3 fatty 
acids in the reversal of the deficit in this gene in the brain. Interestingly, the expression of 
the genes MBP, DRD2, MAL, CNP, MOG, CLDN11, CSRP1, and PLP1 changed in the 
opposite direction in female ST KO mice on the high DHA diet compared to the male ST 
KO mice on a control diet from the previous DBP KO study (Table 2).  
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Figure 6. Expanded Convergent Functional Genomics (CFG) analysis. Using the 
integration of multiple animal model and human lines of evidence, genes were scored that 
significantly changed in two out of three experiments in the brain or blood of ST DBP 
KO mice on the high DHA diet compared to ST DBP KO mice on the low DHA diet. 
Genes changed in the PFC received 1 point; genes changed in the blood received an 
additional 1 point. If the brain and blood direction of change was concordant, the gene 
received an additional 2 points. The other four lines of evidence received a maximum of 
1 point each (for human genetic data: 0.5 points if it was linkage, 1 point if it was 
association; for mouse genetic data: 0.5 points if it was QTL, 1 point if it was transgenic). 
Thus, the maximum possible CFG score for each gene was 8 points. 
 Table 1. Top ST DBP KO gene expression changes in female mice on high DHA vs. low DHA diet. Top candidate genes for which 
there were changes in prefrontal cortex (PFC) and/or blood are shown with a CFG score of 2 points and higher. I – Increased in 
expression, D – decreased in expression, BP – bipolar, MDD – major depressive disorder, PTSD – post traumatic stress disorder. 
Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage or 
Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
CD44 
CD44 antigen D D Yes 
11p13  
BP[68-69] D (Alcohol)
[70]
 I (BP)[71] Abnormal Emotion/Affect Behavior 7.0 
CLIC4 
chloride 
intracellular 
channel 4 
(mitochondrial) 
I D No 1p36.11 BP[72] 
I (PTSD)[73] 
D (Alcohol)[74] I (BP)
[71]
 
(Transgenic) 
Abnormal Emotion/Affect 
Behavior 
5.5 
DRD2 
dopamine 
receptor 2 
I   
11q23.2 
BP[75] 
(Association)  
PTSD[76] 
Alcohol and Drug 
Dependence[77] 
Alcohol Addiction[78] 
Alcohol Dependence[79] 
Alcohol[80-83] 
I (BP)[84] 
D (Depression)[85] 
D (Alcohol)[81] 
D (Delusions) 
[86]
 
Abnormal Emotion/Affect 
Behavior 
Abnormal Circadian 
Rhythm 
(Transgenic) 
Abnormal Emotion/Affect 
Behavior 
5.0 
MBP 
myelin basic 
protein 
I D No 
18q23 
(Association) 
Substance 
Dependence[87] 
BP[88-93]  
D (BP)[94] 
D (Alcohol)[70, 95] 
I (Male BP)[96] 
D (Female BP)[96] 
I (Mood)[97]  5.0 
CDKN1C 
cyclin-dependent 
kinase inhibitor 
1C (P57) 
D   
11p15.4 
(Association) 
BP[93] 
D (MDD)[98] 
 
D (Chronic 
Stress)[99] 
Abnormal Emotion/Affect 
Behavior 
Addiction/Drug Abuse 
4.5 
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 Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage or 
Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
NEFH 
neurofilament, 
heavy 
polypeptide 
I   22q12.2  BP[100-101] 
D (Alcohol)[102] 
D (BP)[103] 
I (Alcohol)[104] 
I 
(Hallucinations) 
[86] 
Addiction/Drug Abuse 
Abnormal Emotion/Affect 
Behavior 
(Transgenic) 
Abnormal Emotion/Affect 
Behavior 
4.5 
PRKAR2B 
protein kinase, 
cAMP 
dependent 
regulatory, type 
II beta 
I D No 
7q22.3  
Panic Disorder[105] 
Alcohol[106-107] 
I (BP)[108] 
D (PTSD)[73]  
(Transgenic) 
Addiction/Drug Abuse 4.5 
CAST 
calpastatin I   
5q15  
Alcohol[109] 
(Association) 
Alcohol[110] 
D (Alcohol)[74]  
(Transgenic) 
Abnormal Circadian 
Rhythm 
4.0 
EFHD1 
EF hand domain 
containing 1 
I I Yes 2q37.1    4.0 
ERBB3 
v-erb-b2 
erythroblastic 
leukemia viral 
oncogene 
homolog 3 
(avian) 
I   12q13.2  Panic Disorder[111-112] 
D (MDD)[98] 
D (BP)[94] D (Mood)
[97]
 
Abnormal Sleep Pattern 
Abnormal Emotion/Affect 
Behavior 
4.0 
GSN 
gelsolin I D No 
9q33.2  
BP[69, 113] 
Alcohol[114] 
D (BP)[108, 115] 
 
 
Addiction/Drug Abuse 
Abnormal Emotion/Affect 
Behavior 
Abnormal Circadian 
Rhythm 
4.0 
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 Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage or 
Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
MAG 
myelin-
associated 
glycoprotein 
I   19q13.12 MDD[116] 
D (MDD)[98, 117] 
D (Alcohol)[70] 
I (Alcohol)[102, 104] 
D (Mood)[97] 
Abnormal Emotion/Affect 
Behavior 
Abnormal Sleep Pattern 
Addiction/Drug Abuse 
Abnormal Circadian 
Rhythm 
4.0 
PPP1R1B 
protein 
phosphatase 1, 
regulatory 
(inhibitor) 
subunit 1B 
I 
 
 
17q12 
Alcohol[118] 
(Association) 
Alcohol[119] 
D (BP)[120]  (Transgenic) Addiction/Drug Abuse 4.0 
SEPT8 
septin 8 
I   5q23.3 MDD[116] D (Alcohol)
[70]
 D (Mood)[97] 
Abnormal Emotion/Affect 
Behavior 
Addiction/Drug Abuse 
Abnormal Circadian 
Rhythm 
4.0 
ESR1 
estrogen receptor 
1 (alpha) 
D   
6q25.1  
(Association) 
Childhood Onset Mood 
Disorder[121] 
Alcohol[110] 
I (Depression)[122]  
Addiction/Drug Abuse 
Abnormal Emotion/Affect 
Behavior 
3.5 
MAL 
myelin and 
lymphocyte 
protein, T-cell 
differentiation 
protein 
I   2q11.1 Alcohol[106] 
D (MDD)[98] 
D (Alcohol)[70] 
I (Alcohol)[102] 
 
I (BP)[123] 
D (BP)[71]  3.5 
ALDH1A1 
aldehyde 
dehydrogenase 
family 1, 
subfamily A1 
I   
9q21.13 
Alcohol[124-125] 
BP[69, 126-127] 
Alcohol[127] 
I (BP)[128]   3.0 
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 Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage or 
Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
APOD 
apolipoprotein D I   
3q29 
BP[129] 
D (MDD)[98] 
D (Alcohol)[70, 130] 
I (Alcohol)[95, 104] 
I (BP)[131] 
 
Abnormal Emotion/Affect 
Behavior 3.0 
CARHSP1 
calcium 
regulated heat 
stable protein 1 
I   
16p13.2 
Alcohol[132] 
BP[133] 
D (Alcohol)[74]  
Abnormal Emotion/Affect 
Behavior 
Abnormal Circadian 
Rhythm 
3.0 
CLDN11 
claudin 11 I   
3q26.2 
BP[69, 72] D (BP)
[94]
  Abnormal Sleep Pattern 3.0 
CNP 
2',3'-cyclic 
nucleotide 3' 
phosphor-
diesterase 
I   17q21.2 Alcohol[134] 
D (MDD)[98] 
D (Alcohol)[70, 74, 135]  
Abnormal Sleep Pattern 
Abnormal Emotion/Affect 
Behavior 
Addiction/Drug Abuse 
3.0 
CRYAB 
crystallin, alpha 
B 
I   11q23.1  Alcohol[80] 
D (Stress 
Disorder)[136] 
I (Alcohol)[102, 104] 
D (PTSD)[73] 
 
Abnormal Emotion/Affect 
Behavior 
Abnormal Circadian 
Rhythm 
3.0 
CTGF 
connective tissue 
growth factor 
I D No 6q23.2 BP[137-138]   
Addiction/Drug Abuse 
Abnormal Emotion/Affect 
Behavior 
Abnormal Circadian 
Rhythm 
3.0 
EVI2A 
ecotropic viral 
integration site 
2a 
I D No 
17q11.2 
Alcohol[109] 
BP[69, 139] 
  
Abnormal Emotion/Affect 
Behavior 
Abnormal Sleep Pattern 
Addiction/Drug Abuse 
3.0 
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 Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage or 
Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
FABP7 
fatty acid 
binding protein 
7, brain 
D   
6q22.31  
Alcohol[80] 
BP[140-142] 
(Association) 
Panic Disorder[143] 
BP[142] 
D (BP)[108]   3.0 
FOXO3A 
forkhead box 
O3a 
I   
6q21  
BP[140-141, 144-146] 
Anxiety, Depression[147] 
Alcohol[80] 
I (BP)[103]  
Abnormal Circadian 
Rhythm 
Abnormal Emotion/Affect 
Behavior 
Addiction/Drug Abuse 
3.0 
GPR37 
G protein-
coupled receptor 
37 
I   7q31.33 BP[148] 
D (MDD)[98] 
D (Alcohol)[70]  
Abnormal Emotion/Affect 
Behavior 3.0 
GRP 
gastrin releasing 
peptide 
D   
18q21.32 
BP[92, 140, 149] 
(Association) 
Panic Disorder[143, 150] 
  
Abnormal Emotion/Affect 
Behavior 
(Transgenic) 
Addiction/Drug Abuse 
3.0 
KIF5C 
kinesin family 
member 5C 
I   
2q23.1  
BP[72, 105] 
Alcohol[124] 
 
D (Mood)[97] 
I (Delusions)[86] 
Abnormal Circadian 
Rhythm 
Abnormal Emotion/Affect 
Behavior 
3.0 
MOG 
myelin 
oligodendrocyte 
glycoprotein 
I   6p22.1 BP[151] 
D (BP)[94] 
D (MDD)[98] 
D (Alcohol)[70] 
 
 
Abnormal Emotion/Affect 
Behavior 3.0 
PRDX2 
peroxiredoxin 2 D   
19p13.13 
MDD[116] 
D (BP)[128] 
I (Alcohol)[152]  
Abnormal Circadian 
Rhythm 
Abnormal Emotion/Affect 
Behavior 
Addiction/Drug Abuse 
3.0 
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 Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage or 
Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
PTN 
pleiotrophin D   
7q33  
BP[69] 
I (Major 
Depression)[153] 
I (Alcohol)[74] 
 
Abnormal Emotion/Affect 
Behavior 3.0 
QDPR 
quinoid 
dihydropteridine 
reductase 
I   4p15.31 BP[154] D (BP)
[103]
  
Abnormal Emotion/Affect 
Behavior 
Abnormal Circadian 
Rhythm 
3.0 
SPTBN1 
spectrin, beta, 
non-erythrocytic 
1 
I D No 
2p16.2 
BP[139] 
Alcohol[80, 106] 
  
Abnormal Emotion/Affect 
Behavior 
Addiction/Drug Abuse 
3.0 
SYT2 
synaptotagmin II I   
1q32.1 
Panic Disorder[112] 
Alcohol[80] 
D (BP)[103]  Abnormal Emotion/Affect Behavior 3.0 
CAMK4 
calcium/calmod-
ulin-dependent 
protein kinase IV 
I   5q22.1 Alcohol[109]   
Abnormal Emotion/Affect 
Behavior 
Addiction/Drug Abuse 
(Transgenic) 
Addiction/Drug Abuse 
2.5 
CPM 
carboxy-
peptidase M 
I   12q15  BP[155]  I (Mood)
[97]
  
2.5 
CSRP1 
cysteine and 
glycine-rich 
protein 1 
I   
1q32.1  
Panic Disorder[112] 
Alcohol[80] 
D (Alcohol)[70, 156] 
 
  
2.5 
DRD1A 
dopamine 
receptor D1A 
I   
5q35.2  
BP[157] 
Panic Disorder[158] 
  
Addiction/Drug Abuse 
Abnormal Emotion/Affect 
Behavior 
(Transgenic) 
Addiction/Drug Abuse 
2.5 
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 Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage or 
Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
GAB1 
growth factor 
receptor bound 
protein 2-
associated 
protein 1 
I   4q31.21 BP[154, 159] D (Alcohol)
[74]
   
2.5 
GPR6 
G protein-
coupled receptor 
6 
I   
6q21 
(Association) 
BP[93, 141, 144-146] 
Anxiety, Depression[147] 
Alcohol[80] 
  
Abnormal Circadian 
Rhythm 
Abnormal Emotion/Affect 
Behavior 
Addiction/Drug Abuse 
2.5 
LITAF 
LPS-induced TN 
factor 
I D No BP[105, 133]    2.5 
MOBP 
myelin-
associated 
oligodendrocytic 
basic protein 
I   3p22.2 
D (BP)[94] 
D (MDD)[98] 
D (Alcohol)[70] 
I (Alcohol)[102, 104] 
 
Abnormal Emotion/Affect 
Behavior 
Abnormal Circadian 
Rhythm 
2.5 
NDRG1 
N-myc 
downstream 
regulated gene 1 
I D No BP[69, 146, 149]    2.5 
PTTG1 
pituitary tumor-
transforming 1 
D   5q33.3 BP[36, 160]  
I (Postpartum 
Depression) [161]  2.5 
RASGRP2 
RAS, guanyl 
releasing protein 
2 
I D No BP[69, 162]    2.5 
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 Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage or 
Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
RGS9 
regulator of G-
protein signaling 
9 
I   17q24.1  D (Mood)[97] 
Abnormal Sleep Pattern 
Abnormal Emotion/Affect 
Behavior 
Addiction/Drug Abuse 
2.5 
ST18 
suppression of 
tumorigenicity 
18 
I   8q11.23  BP[92, 140] D (Alcohol)
[130]
   
2.5 
SYN2 
synapsin II D   3p25 
I (Major Depression 
Suicide 
Completer)[163-164] 
D (Alcohol)[104] 
D (BP)[165] 
 
Abnormal Circadian 
Rhythm 
Abnormal Emotion/Affect 
Behavior 
Abnormal Sleep Pattern 
2.5 
CACNA2D1 
calcium channel, 
voltage-
dependent, 
alpha2/delta 
subunit 1 
D   
7q21.11  
Panic Disorder[105] 
Alcoholism[166] 
BP[139, 145] 
  
Abnormal Emotion/Affect 
Behavior 2.0 
COL11A1 
collagen, type 
XI, alpha 1 
I   
1p21.1 
Alcohol[124, 167-168] 
Depression, Alcohol[169] 
  
Addiction/Drug Abuse 
Abnormal Sleep Pattern 
Abnormal Emotion/Affect 
Behavior 
2.0 
CPLX3 
complexin 3 I   15q24.1  I (Mood)
[97]
  
2.0 
ELOVL7 
ELOVL family 
member 7, 
elongation of 
long chain fatty 
acids (yeast) 
I   5q12.1 D (Alcohol)[74]   2.0 
47
 
 
 Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage or 
Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
EOMES 
eomesodermin 
homolog 
(Xenopus laevis) 
D   3p24.1   
Abnormal Emotion/Affect 
Behavior 
Abnormal Circadian 
Rhythm 
(Transgenic) 
Abnormal Emotion/Affect 
Behavior 
2.0 
FA2H 
fatty acid 2-
hydroxylase 
I   16q22.3  
I (Mood)[97] 
D 
(Delusions)[86] 
 
2.0 
HAPLN2 
hyaluronan and 
proteoglycan 
link protein 2 
I   
1q23.1 
Alcoholism[167] 
BP[162] 
 
  
Addiction/Drug Abuse 
Abnormal Sleep Pattern 
Abnormal Emotion/Affect 
Behavior 
2.0 
LASS2 
LAG1 homolog, 
ceramide 
synthase 2 
I   1q21.2 D (Alcohol)[74]   2.0 
LGI2 
leucine-rich 
repeat LGI 
family, member 
2 
I   
4p15.2 
(Association) 
BP, Substance 
Dependence[87] 
   
2.0 
MGP 
matrix Gla 
protein 
I   12p12.3  D (Alcohol)[170]  2.0 
PDE10A 
Phospho-
diesterase 10A 
I   
6q27 
(Association) 
MDD[171] 
   
2.0 
PDE8A 
phosphor-
diesterase 8A 
I   15q25.3 D (MDD)[98]   2.0 
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 Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage or 
Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
PENK1 
preproen-
kephalin 1 
I   8q12.1   
Addiction/Drug Abuse 
(Transgenic) 
Addiction/Drug Abuse 
2.0 
PLEKHH1 
pleckstrin 
homology 
domain 
containing, 
family H (with 
MyTH4 domain) 
member 1 
I   14q24.1 D (Alcohol)[74]   2.0 
PLP1 
proteolipid 
protein (myelin) 
1 
I   Xq22.2 
D (BP)[94] 
D (MDD)[98, 117]  
D (Alcohol)[74] 
I (Alcohol)[104] 
  
2.0 
SCN7A 
sodium channel, 
voltage-gated, 
type VII, alpha 
D   
2q24.3 
BP[105] 
Alcohol[124] 
  
Abnormal Circadian 
Rhythm 
Abnormal Emotion/Affect 
Behavior 
2.0 
SDC4 
syndecan 4 D   
20q13.12 
Alcohol[109] 
BP[172] 
  
Addiction/Drug Abuse 
Abnormal Emotion/Affect 
Behavior 
2.0 
SESN3 
sestrin 3 D   11q21 I (Alcohol)
[74]
   
2.0 
SLC44A1 
solute carrier 
family 44, 
member 1 
I D No 
    
2.0 
TNNT2 
troponin T2, 
cardiac 
D   
1q32 
Panic Disorder[112] 
Alcohol[80] 
  
Abnormal Emotion/Affect 
Behavior 2.0 
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 Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage or 
Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
TPBG 
trophoblast 
glycoprotein 
I   6q14.1  
I (Valproate 
Treated-Human 
NBFL 
Cells)[103] 
 
2.0 
TSPAN2 
tetraspanin 2 I D No     2.0 
TTYH2 
tweety homolog 
2 (Drosophila) 
I   17q25.1 D (Alcohol)[74]   2.0 
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 Table 2. Top ST DBP KO gene expression changes in male mice on high DHA vs. low DHA diet. Top candidate genes for which 
there were changes in prefrontal cortex (PFC) and/or blood are shown with a CFG score of 2 points and higher. I – Increased in 
expression, D – decreased in expression, BP – bipolar, MDD – major depressive disorder, PTSD – post traumatic stress disorder. 
Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage 
or Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
TFRC 
transferrin receptor 
I I Yes 3q29 BP[92, 173-174] 
Alcohol[175] 
  
Abnormal Emotion/Affect 
Behavior 
5.0 
FOS 
FBJ osteosarcoma 
oncogene D   
14q24.3 
BP [69] 
Alcohol[109] 
Simple Phobia[176] 
I (BP)[177] I (PTSD)
[178] 
(Stress)[179-181] 
Abnormal Sleep Pattern 
Abnormal Emotion/Affect 
Behavior 
(Transgenic) 
Abnormal Emotion/Affect 
Behavior,  
Abnormal Sleep Pattern 
4.5 
PAFAH1B1/LIS1 
platelet-activating 
factor 
acetylhydrolase, 
isoform 1b, beta1 
subunit 
D   17p13.3 (Association) 
BP[182] 
I (Alcohol)[70] 
D (Chronic 
Stress)[99] 
D (Mood)[97] 
Abnormal Emotion/Affect 
Behavior 
Abnormal Sleep Pattern 
Addiction/Drug Abuse 
4.5 
SFPQ 
splicing factor 
proline/glutamine 
rich 
(polypyrimidine 
tract binding protein 
associated) 
I D No 1p34.3 I (BP)
[108]
 
I (MDD)[153] 
I (Social 
Isolation)[183] 
Abnormal Emotion/Affect 
Behavior 
Addiction/Drug Abuse 
4.5 
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 Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage 
or Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
NDUFAB1 
NADH 
dehydrogenase 
(ubiqui) 1, 
alpha/beta 
subcomplex, 1 
I   16p12.1  (Association) 
BP[92, 105, 184] 
D (BP)[185] D (Chronic Stress)[99]  
4.0 
ARF3 
ADP-ribosylation 
factor 3 
I   12q13.12 Panic Disorder[111-
112]
 
D (Alcohol)[70] D (Chronic Stress)[99]  
3.5 
PTTG1 
pituitary tumor-
transforming 1 
D I No 5q33.3  
BP[36, 160]  
I (Postpartum 
Depression 
PBMC)[161] 
 
3.5 
BNIP3L 
BCL2/adenovirus 
E1B interacting 
protein 3-like 
D I No 8p21.2 
BP[72, 140, 186]   
Abnormal Emotion/Affect 
Behavior 
3.0 
CNR1 
cannabinoid 
receptor 1 (brain) 
I   6q15 (Association) 
PTSD[187] 
  
Abnormal Emotion/Affect 
Behavior 
Addiction/Drug Abuse 
(Transgenic) 
Addiction/Drug Abuse, 
Abnormal Emotion/Affect 
Behavior 
3.0 
DSC2 
desmocollin 2 
D   18q12.1 
BP[188] 
D (BP)[189] 
I (MDD)[189] 
D (Alcohol)[70] 
 
Addiction/Drug Abuse 
Abnormal Emotion/Affect 
Behavior 
3.0 
HSPA4 
heat shock protein 4 
D   5q31.1 
MDD[116]  
D (Stress) [179, 
181]
 
Addiction/Drug Abuse 
Abnormal Emotion/Affect 
Behavior 
Abnormal Circadian 
Rhythm 
3.0 
MAX 
MYC associated 
factor X 
D   14q23.3 BP[72] 
Alcohol[109] 
 I (BP)[71] 
Abnormal Sleep Pattern 
Abnormal Emotion/Affect 
Behavior 
3.0 
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 Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage 
or Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
MTDH 
Metadherin 
D   8q22.1 
BP[72, 190]  
D (Chronic 
Stress)[99] 
Abnormal Emotion/Affect 
Behavior 
3.0 
SLC2A3 
solute carrier family 
2 (facilitated 
glucose transporter), 
member 3 
I   12p13.31 
Alcohol[109]  
I (Chronic 
Stress)[99] 
Abnormal Circadian 
Rhythm 
Abnormal Emotion/Affect 
Behavior 
Abnormal Sleep Pattern 
Addiction/Drug Abuse 
3.0 
TMX4 
thioredoxin-related 
transmembrane 
protein 4 
I   20p12.3 
BP[133, 172, 186, 191-192]  
D (Chronic 
Stress)[99] 
Abnormal Emotion/Affect 
Behavior 
Addiction/Drug Abuse 
Abnormal Circadian 
Rhythm 
3.0 
ADAR 
adenosine 
deaminase, RNA-
specific 
I   1q21.3  
Alcohol[167]  
D (Chronic 
Stress)[99]  
2.5 
ATRX 
alpha 
thalassemia/mental 
retardation 
syndrome X-linked 
homolog (human) 
I   Xq21.1 D (Alcohol)[156]  Abnormal Emotion/Affect Behavior 
2.5 
GPRC5B 
G protein-coupled 
receptor, family C, 
group 5, member B 
D   16p12.3  
BP[92, 105] D (MDD)
[98] 
  
2.5 
LUC7L2 
LUC7-like 2 (S. 
cerevisiae) 
I D No 7q34  Unipolar[129] 
BP[69] 
   
2.5 
PNN 
Pinin 
I   14q21.1 
Alcohol[109] I (Alcohol)
[74]
   
2.5 
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 Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage 
or Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
RALY 
hnRNP-associated 
with lethal yellow 
D   20q11.22 
BP[69, 172]   
Abnormal Emotion/Affect 
Behavior 
2.5 
SFRS5 
splicing factor, 
arginine/serine-rich 
5 (SRp40, HRS) 
I   14q24.1  Simple Phobia[176] 
Alcohol[109]BP[69] 
I (Stress)[136]   2.5 
TEF 
thyrotroph 
embryonic factor 
I   
22q13.2 
(Association) 
Unipolar[193] BP[91, 
100] Panic 
Disorder[158] 
  
Abnormal Emotion/Affect 
Behavior 
2.5 
UBE2D2 
ubiquitin-
conjugating enzyme 
E2D 2 
MI   5q31.2  
BP[139] D (Stress)
[136]
   
2.5 
VAMP2 
vesicle-associated 
membrane protein 2 
I   17p13.1 
Alcohol[109] 
I (Mood 
Disorders)[194]   
2.5 
YWHAG 
tyrosine 3-
monooxygenase/try
ptophan 5-
monooxygenase 
activation protein, 
gamma polypeptide 
I   7q11.23 
Alcoholism[166] D (Alcohol)
[135]
   
2.5 
CAP1 
CAP, adenylate 
cyclase-associated 
protein 1 (yeast) 
D   1p34.2 D (BP)[115]   2.0 
COL16A1 
collagen, type XVI, 
alpha 1 
I   1p35.2 D (BP)[195]   2.0 
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 Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage 
or Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
DCT 
dopachrome 
tautomerase 
I   13q32.1 BP[100] Panic 
Disorder[158] 
  
Abnormal Emotion/Affect 
Behavior 
2.0 
FMN2 
formin 2 
I   
1q43  
Panic Disorder[111, 
196]
 
Alcohol[118] 
  
Addiction/Drug Abuse 
Abnormal Emotion/Affect 
Behavior 
2.0 
FSCN1 
fascin homolog 1, 
actin bundling 
protein 
(Strongylocentrotus 
purpuratus) 
I   
7p22.1  
Anxiety, 
Depression[147] 
Alcohol[109] 
  
Abnormal Circadian 
Rhythm 
2.0 
GNG4 
guanine nucleotide 
binding protein (G 
protein), gamma 4 
D   1q42.3 BP[126, 129] Panic 
Disorder[158] 
  
Abnormal Sleep Pattern 
Abnormal Emotion/Affect 
Behavior 
2.0 
HERC5 
hect domain and 
RLD 5 
D   4q22.1  D (Chronic Stress)[99]  
2.0 
IGH-6 
immunoglobulin 
heavy chain 6 
(heavy chain of 
IgM) 
D   14q32.33  
Anxiety[197]   
Abnormal Emotion/Affect 
Behavior 
Abnormal Circadian 
Rhythm 
2.0 
PBX3 
pre B-cell leukemia 
transcription factor 
3 
D   9q33.3  Alcoholism[114] 
BP[69, 113] 
  
Addiction/Drug Abuse 
Abnormal Emotion/Affect 
Behavior 
2.0 
PRMT1 
protein arginine N-
methyltransferase 1 
I   19q13.33 
BP[69]   
Addiction/Drug Abuse 
Abnormal Circadian 
Rhythm 
Abnormal Emotion/Affect 
Behavior 
2.0 
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 Gene Symbol/ 
Name 
Mouse 
PFC 
Mouse 
Blood 
Mouse Brain-
Blood 
Concordance 
Human Genetic 
Evidence (Linkage 
or Association) 
Human Postmortem 
Brain Evidence 
Human Blood 
Evidence 
Mouse Genetic Evidence 
(QTL, TG) 
CFG 
Score 
RGS5 
regulator of G-
protein signaling 5 
I   1q23.3  
Alcohol[167] BP[162]   
Addiction/Drug Abuse 
Abnormal Emotion/Affect 
Behavior 
2.0 
S100A5 
S100 calcium 
binding protein A5 
D   1q21.3  
Alcohol[167]   
Abnormal Emotion/Affect 
Behavior 
Abnormal Sleep Pattern 
2.0 
SEMA5A 
sema domain, seven 
thrombospondin 
repeats (type 1 and 
type 1-like), 
transmembrane 
domain (TM) and 
short cytoplasmic 
domain, 
(semaphorin) 5A 
D   
5p15.31 
Alcohol[124, 198] 
BP[69] 
(Association) 
BP, Substance 
Dependence[87] 
   
2.0 
TIMM9 
translocase of inner 
mitochondrial 
membrane 9 
homolog (yeast) 
I   14q23.1 D (Stress)[136]   2.0 
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*CD44
*CLIC4
*DRD2
*MBP
*CDKN1C     
*NEFH PRKAR2B
CAST EFDH1 *ERBB3 GSN
*MAG PPP1R1B     *SEPT8
ESR1 *MAL
ALDH1A1     APOD     CARHSP1     CLDN11     CNP     CRYAB     CTGF
EVI2A     FABP7     FOXO3A     GPR37     GRP     *KIF5C     MOG
PRDX2     PTN     QDPR     SPTBN1     SYT2
5.0
4.0
3.5
Mouse Blood Biomarker Candidate
Mouse Brain-Blood Concordance
*Human Blood Biomarker Evidence
Human Postmortem Brain Evidence
Human Genetic Evidence
4.5
3.0
5.5
A.
7.0
 
TFRC
*FOS
*PAFAH1B1
*SFPQ
*NDUFAB1
*ARF3 PTTG1
BNIP3L CNR1 DSC2 *HSPA4
*MAX *MTDH *SLC2A3 *TMX4
4.5
3.5
3.0
4.0
Mouse Blood Biomarker Candidate
Mouse Brain-Blood Concordance
*Human Blood Biomarker Evidence
Human Postmortem Brain Evidence
Human Genetic Evidence
B.
5.0
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Figure 7. Top candidate gene changes in ST DBP KO mice on high vs. low DHA diet. A. 
Female mice; B. Male mice. 
59 
Ingenuity 
 To discover the molecular networks, biological functions and canonical pathways 
of the top candidate genes for therapy with DHA, Ingenuity Software was employed 
(Table 3, A and B). The list of genes from Tables 1 and 2 were separately evaluated using 
the software. Of particular interest, included in the molecular networks involving the top 
changed genes for female ST DBP KO mice were neurological disease and development 
of the nervous system. For top biological functions, psychological disease was associated 
with 29 of the genes (called molecules in Ingenuity Software) and neurological disease 
was connected to 48 of the genes. In the category of molecular and cellular functions, 
more than 30 of the genes on the female list were associated with cell death, cellular 
development, or cell growth and proliferation. Looking further at the table, top 
physiological system functions include nervous system development and behavior. 
Finally the top canonical pathway for the top genes changed in female ST DBP KO mice 
on the high DHA diet compared to their counterparts on the low DHA diet was dopamine 
receptor signaling.  
The Ingenuity pathways for the 40 genes from male data (Table 2) did not have as 
high of concordance of genes as was seen for female mice, as the numbers of genes in the 
“Number of Molecules” column are much lower. Nevertheless, many genes were 
included in the top pathways. Neurological disease (6 genes) and skeletal and muscular 
disorders (11 genes) were the top biological functions. In the category of molecular and 
cellular functions, many genes were associated with cell cycle, gene expression, cellular 
development, cell growth and proliferation and cell signaling. Looking further at the 
table, top physiological system functions include embryonic, connective tissue, and 
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nervous system development. Finally, the top canonical pathways for the top genes 
changed in male ST DBP KO mice on the high DHA diet compared to their counterparts 
on the low DHA diet included CCRS signaling in macrophages, ERK5 signaling and 
Reelin signaling in neurons.  
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Table 3. Ingenuity pathway analysis of top candidate genes. A. Analysis of the top 72 
candidate genes in female ST DBP KO mice on the high DHA diet compared to female 
ST DBP KO mice on the low DHA diet (CFG score of 2.0 and above); B. Analysis of the 
top 40 candidate genes in male ST DBP KO mice on the high DHA diet compared to ST 
DBP KO mice on the low DHA diet (CFG score of 2.0 and above). 
A. 
Associated Network Functions
Neurological Disease, Cell Morphology, Nervous System Development and Function
Cell-To-Cell Signaling and Interaction, Cellular Assembly and Organization, Cell Cycle
Neurological Disease, Cancer, Reproductive System Disease
Cell Signaling, Nucleic Acid Metabolism, Small Molecule Biochemistry
Molecular Transport, Cardiovascular Disease, Genetic Disorder
Diseases and Disorders p-value Number of Molecules
Neurological Disease 3.12E-12 - 8.88E-03 48
Psychological Disorders 1.64E-10 - 5.48E-03 29
Genetic Disorder 2.28E-10 - 8.88E-03 57
Skeletal and Muscular Disorders 4.09E-09 - 8.88E-03 32
Cancer 4.45E-07 - 8.88E-03 35
Name p-value Number of Molecules
Cell Death 8.15E-08 - 8.88E-03 31
Cellular Development 5.37E-07 - 8.88E-03 32
Cellular Assembly and Organization 7.90E-07 - 8.88E-03 24
Cell Morphology 1.67E-06 - 8.88E-03 17
Cellular Growth and Proliferation 4.86E-06 - 8.88E-03 31
Name p-value Number of Molecules
Nervous System Development and Function 1.67E-06 - 8.88E-03 27
Behavior 6.03E-06 - 8.88E-03 13
Skeletal and Muscular System Development and Function 1.17E-05 - 8.88E-03 14
Organ Development 1.95E-05 - 8.88E-03 14
Reproductive System Development and Function 1.95E-05 - 8.88E-03 9
Name p-value Ratio
Dopamine Receptor Signaling 3.25E-04 4/93 (0.043)
cAMP-mediated Signaling 6.24E-04 5/161 (0.031)
G-Protein Coupled Receptor Signaling 2.07E-03 5/220 (0.023)
PXR/RXR Activation 3.88E-03 3/91 (0.033)
IGF-1 Signaling 7.97E-03 3/100 (0.03)
30
20
2
15
Female Data
Top Bio Functions
Top Networks
Molecular and Cellular Functions
Physiological System Development and Function
Top Canonical Pathways
Score
45
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B. 
Associated Network Functions
Neurological Disease, Skeletal and Muscular Disorders, Cell Cycle
Cellular Development, Cellular Growth and Proliferation, Cancer
Cancer, Renal and Urological Disease, Post-Translational Modification
Genetic Disorder, Skeletal and Muscular Disorders, Inflammatory Disease
Diseases and Disorders p-value Number of Molecules
Neurological Disease 3.53E-05 - 4.77E-02 6
Skeletal and Muscular Disorders 3.53E-05 - 4.77E-02 11
Cancer 1.11E-04 - 4.82E-02 20
Immunological Disease 1.85E-03 - 3.90E-02 14
Reproductive System Disease 2.46E-03 - 1.23E.02 9
Name p-value Number of Molecules
Cell Cycle 8.81E-05 - 3.87E-02 9
Gene Expression 1.64E-04 - 4.82E-02 7
Cellular Development 1.83E-04 - 4.82E-02 12
Cellular Growth and Proliferation 1.83E-04 - 4.82E-02 14
Cell-to-Cell Signaling and Interaction 1.94E-04 - 4.35E-02 8
Name p-value Number of Molecules
Embryonic Development 8.81E-05 - 4.58E-02 12
Connective Tissue Development and Function 1.83E-04 - 4.58E-02 6
Nervous System Development and Function 1.94E-04 - 4.58E-02 8
Hair and Skin Development and Function 2.10E-04 - 4.58E-02 7
Renal and Urological System Development and Function 2.10E-04 - 2.92E-02 5
Name p-value Ratio
CCRS Signaling in Macrophages 1.22E-02 2/92 (0.022)
ERK5 Signaling 1.22E-02 2/71 (0.028)
Reelin Signaling in Neurons 1.46E-02 2/78 (0.026)
IL-1 Signaling 2.11E-02 2/106 (0.019)
IGF-1 Signaling 2.15E-02 2/100 (0.02)
Physiological System Development and Function
Top Canonical Pathways
Top Networks
Score
48
26
6
Top Bio Functions
Molecular and Cellular Functions
Male Data
2
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Alcohol consumption in ST DBP KO mice and P rats 
Given the high rate of co-morbidity of alcoholism and bipolar disorder in humans, 
and our previous study showing increased alcohol intake in ST DBP KO compared to ST 
WT mice [31], alcohol intake was monitored in DBP KO mice on a high or low DHA 
diet. In studies using male ST DBP KO mice, mice on a diet high in DHA for 14 and 28 
days drank significantly less alcohol than mice on a diet low in DHA during the same 
amount of time (Figure 8. (a and b) 14 days of DHA treatment, t-test p-value = 0.002. (c 
and d) 28 days of DHA treatment, t-test p-value = 0.04). No significant differences in 
water consumption were observed (data not shown), which shows mice had a preference 
for alcohol and were not simply drinking more fluids. 
The effects of DHA on another rodent model, the alcohol-preferring (P) rat, were 
also tested. A dose-dependent effect was observed, where P rats on a diet high in DHA 
drank significantly less alcohol over a 14 day period than did P rats on a diet low in DHA 
(Figure 9 (a and b) t-test p-value = 0.01 comparing alcohol consumption in rats on the 
high verses low DHA diets). 
64 
 
Figure 8. Effects of DHA on ethanol consumption in male ST DBP KO mice. Mice on a 
diet supplemented with either low or high DHA were subjected to alcohol free-choice 
drinking paradigm for 4 weeks. (a and b) Fluid consumption (water or 10% v/v ethanol) 
was monitored for a period of 2 weeks (14 days); (c and d) Fluid consumption (water or 
10% v/v ethanol) was monitored for a period of 4 weeks (28 days) with an acute stressor 
(behavioral challenge tests represented by the dotted vertical line) on day 21. * indicates 
p-value ≤ 0.05. 
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a. b.
 
Figure 9. Effects of DHA on ethanol consumption in male alcohol-preferring (P) rats. P 
rats were placed on one of three diets, (1) low DHA diet, (2) control diet, or (3) high 
DHA diet. Rats were given continuous free-choice access in the home cage to 15% v/v 
ethanol and water. Ethanol intake was measured daily throughout the experiment. Fluid 
consumption from both bottles was monitored for a period of 2 weeks (14 days). * 
indicates p-value ≤ 0.05. 
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Discussion 
The human body does not endogenously produce enough of the essential omega-3 
fatty acid, DHA, and therefore it must be obtained from the diet to maintain adequate 
levels in phospholipids of the brain and blood [199]. This fatty acid is important for 
proper brain development and function, and deficits have been shown in the postmortem 
brains of patients with major depressive disorder and bipolar disorder [20-21]. Similar to 
our previous results with ST mice on a control diet [31], there was a significant difference 
between ST DBP KO mice and ST WT mice in the forced swim test and the open-field 
test when on a low DHA diet. As before, the ST DBP KO mice move significantly more 
than the ST WT mice. However, when mice were fed a diet high in DHA, there was no 
longer a significant difference in movement times (on the forced swim test for females, 
and on the open-field test for males). Likewise, the movement times were intermediate of 
those observed for the mice on the low DHA diet.  
The forced swim test and open-field locomotion tracking tests have been used in 
studies to assess and correlate movement to mood [31, 200]. More immobility during 
both the forced swim and open-field tests correlates with depression, whereas heightened 
mobility during these tests correlates with hyperactivity and manic-like behavior. In 
normal humans, chronic stress can induce depression [200], whereas stress can induce 
mania in patients with bipolar disorder [40]. In our previous study, we showed that NST 
DBP KO mice present a depressed phenotype by moving significantly less than NST WT 
mice at baseline, but with chronic and acute stress they become more active and exhibit 
impulsive behavior (by increasing time spent in the center of the open field), instead of a 
decrease in overall locomotion as their ST WT counterparts exhibit. According to our 
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present results, our ST WT mice on a low DHA diet exhibit depressed behavior (low 
mobility in the forced swim and open-field tests), whereas ST DBP KO mice on the low 
DHA diet exhibit manic-like hyperactive behavior (high mobility and impulsivity), as 
would be expected. When given a diet high in DHA, however, the ST KO and ST WT 
mice no longer have polarized results, and instead have mobility times that are not 
significantly different and are in-between the extreme values of their counterparts on the 
low DHA diet, indicating the possibility of stabilized mood due to DHA in the diet. 
When separating the results based on gender, significance was reached for the 
forced swim between the female ST WT mice on the different diets, suggesting DHA 
may have had an anti-depressant effect on these mice. Conversely, significance was 
reached for locomotion values for male ST KO mice in the open field on the different 
diets, suggesting DHA may have had an anti-manic effect on these mice. A trend towards 
anti-manic behavior was seen for female mice on the forced swim test, and with a larger 
cohort of animals statistical significance may be reached. Indeed, our genetic results 
indicated gene expression profiles congruent with anti-manic outcomes. Figure 10 depicts 
a hypothetical scheme derived from all of our behavioral data. 
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High mood
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DBP KO (Low DHA diet)
DBP KO (High DHA diet)
DBP WT (High DHA diet)
DBPWT (Low DHA diet) 
 
Figure 10. High DHA diet has a stabilizing effect on mood in ST DBP KO and WT mice. 
The high manic-like behavior seen in ST DBP KO mice on the low DHA diet and the 
depressed behavior of the ST WT mice on the low DHA diet are stabilized to normal 
behavior when given the high DHA diet. 
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 Using the CFG approach we were able to generate a list of 40 genes for males and 
72 genes for females that were changed in at least two out of three microarray replicates 
and which had been connected to bipolar disorder or related disorders in published 
literature. Many of these genes were changed in the opposite direction in the PFC of the 
mice on the high DHA diet compared to the postmortem PFC of bipolar patients or 
patients with related disorders. This shows the potential of DHA at reversing the genetic 
alterations seen in bipolar brains. Congruently, Ingenuity pathways for females showed 
that many of the genes changed by DHA have roles in neurological disease and 
psychological disorder, as well as behavior and neuron development. While the genes 
changed by DHA in males have roles in neurological disease, there are not as many 
disorder relevant genes as for females. Our genetic data reveals candidate genes that may 
have future potential in bipolar research and as targets for drug therapy. 
 Another goal of our genetic studies was to discover potential blood biomarkers. 
Blood biomarkers are genes that change in expression in the blood in concordance with 
the changes in the brain, and thus have potential as diagnostic tools for monitoring 
response to treatment [43]. We found three genes which may serve as biomarkers for 
monitoring response to DHA treatment. Specifically, the level of expression of CD44, 
EFDH1 or TFRC in the blood could be monitored during DHA supplementation, to 
determine subsequent genetic expression changes in the brain. If levels did not change, 
DHA may not be adequately taken up into or affecting the brain or blood. This is 
preliminary evidence and would need to be confirmed by future studies. 
When looking at the genes from Table 1, we noticed that female mice on the high 
DHA diet had significant increases in the amount of myelin associated proteins, 
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specifically MBP, MAL, MAG, CLDN11, PLP1, MOG, and MOBP. These genes were 
all increased in the PFC of female mice on the high DHA diet as compared to the female 
mice on the low DHA diet. Conversely, these genes are decreased in human postmortem 
PFC of bipolar patients, depressed, and alcoholic patients. Other studies have also 
reported decreases in myelin genes in the postmortem brains of bipolar patients [94]. 
DHA may be exerting its effects by upregulating myelin production in oligodendrocytes, 
bringing neurotransmission back to normal levels.  
Also of particular interest from the female list of genes is the upregulation of 
genes related to dopamine signaling. Particularly, DRD2, the gene producing the 
dopamine D2 receptor, and DRD1A, which encodes the D1 receptor A subunit, were both 
upregulated in female ST DBP KO mice on the high DHA diet compared to their 
counterparts on the low DHA diet. Studies have shown altered dopaminergic 
transmission in bipolar patients [13], so the upregulation of these receptors may represent 
the fine-tuning of dopaminergic signaling in the PFC of the female mice on the high diet, 
leading to modulated mood. 
In addition to their involvement in neurological disease and neuron development, 
many of the top candidate genes for males are involved in gene expression regulation and 
cell signaling. Some of the top male candidate genes are associated with Reelin signaling. 
Interestingly, Reelin expression is regulated by dopamine responsive promoters [201]. 
Changes in dopamine signaling, which are seen in bipolar patients, could affect promoter 
epigenetics, leading to altered expression of genes involved in Reelin signaling, affecting 
neuronal outgrowth. In addition, transcription factors, such as SFPQ were increased in 
the PFC of male mice, which could further alter gene expression by binding to histone 
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deacetylases. Though there was no overlap between the genes changed in males verses 
females, pathways in which these genes are associated did overlap and it appears that 
DHA may be affecting more upstream proteins in the females and affecting their 
downstream effectors in males.  
Bipolar disorder often occurs with co-morbid alcoholism in humans and our 
previous data showed that DBP KO mice drink significantly more alcohol than their WT 
littermates. Over a two week and four week period, male ST KO mice on the high DHA 
diet drank significantly less total ethanol than male ST KO mice on the low DHA diet. 
Similarly, over two weeks, P rats drank significantly less ethanol when on the high DHA 
diet compared to P rats on the low DHA diet, with a dose-dependent trend for P rats on a 
control diet. It would be interesting to do genetic testing on these mice, as was performed 
for the male and female mice in the other experiments to discover potential candidate 
genes for bipolar disorder with co-morbid alcoholism and possible blood biomarkers, as 
well. It would also be interesting to see if NST DBP KO mice, which model the 
depressive aspect of bipolar disorder, drink less alcohol with increased DHA in their diet. 
As with our previous observations, an increased number of animals needs to be tested to 
confirm our results. Nevertheless, these studies suggest a potential application of DHA 
supplementation in decreasing alcohol consumption. 
For these studies, we wanted to ensure that responses to DHA could be observed, 
so we chose extremes diets, with trace amounts of DHA in the low diet compared to 
extensive amounts in the high diet. Indeed, in Western industrialized countries, the diet 
consists of high levels of saturated fat with a large omega-6/omega-3 ratio at 15:1 [202]. 
Though we were able to reach significance for the effects of DHA on behavioral 
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outcomes, a control diet with an average amount of DHA, as was used for the rat data, 
would also be informative and will be used in future studies.  
Although our studies have yielded significant data, there are some limitations that 
are worth mentioning. One limitation is that our mouse model is a knockout of only one 
gene, however, bipolar disorder is likely induced by mutations or deletions of numerous 
genes. Nevertheless, we were able to model many aspects of the disease, with the mice 
showing depressed behavior at baseline, and manic-like, impulsive behavior when 
stressed. Another drawback is that we only performed two behavioral analyses on these 
mice. It would be interesting to see how they perform on memory and anxiety tests to see 
if there are deficits or changes in these outcomes, as cognition impairment and stress are 
linked to bipolar disorder [40, 203]. It would have also been helpful to test NST DBP KO 
and WT mice, as was performed in our previous study. In that study, NST DBP KO mice 
showed depressed behavior at baseline, and it would be interesting to know if DHA’s 
anti-depressant effects can be seen in these mice in addition to the ST WT mice. Another 
restriction of our study is that we only looked at the PFC as the brain region to study 
changes in gene expression. It would also be informative to study the effects of DHA in 
other brain regions, such as the amygdala, that have been associated with bipolar disorder 
[204-205]. The fact that our genetic ranking is dependent on the research field, as it is 
based on present, published data, is another limitation of our study. In this sense, genes 
that have not yet been connected with bipolar disorder, but still have important roles in 
the disease, may be omitted from the list or ranked low due to lack of sources discovering 
this role. With this in mind, our CFG analysis will improve with time, as more significant 
evidence is being published, and roles of genes involved in the disorder are discovered. A 
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final concern of this study is that there were no overlaps between the genes on the male 
list and the female list. Perhaps DHA is affecting different genes of similar pathways in 
males and females, or the deletion of DBP affects the brains and blood of females in a 
different way than males. Indeed further studies need to be done on a larger cohort of 
mice to reach definitive conclusions. 
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Conclusion 
DHA can potentially serve as a mood stabilizer for bipolar disorder patients based 
on our behavioral data in a mouse model of the disorder and molecular data obtained 
from the brain and blood of these animals. Likewise, DHA reduced alcohol intake in 
these mice and in an additional rodent model, the alcohol-preferring (P) rat. Although 
promising, our studies suggest further work is necessary to discover the potential of DHA 
as a mood stabilizer and alcohol suppressant in rodents, and its implications for humans 
with bipolar disorder. 
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CHAPTER III: IMPLICATIONS AND FUTURE DIRECTIONS 
 In this study we were able to further validate the DBP KO as a potential rodent 
model of bipolar disorder. We replicated the significant extremes in behavioral results 
between ST DBP KO and ST WT mice when fed a low DHA diet using forced swim and 
open-field movement tracking behavioral tests. However, when fed a diet high in DHA, 
there was no longer a significant difference between groups. Indeed, values fell between 
the extremes of the two groups, suggesting a balance of behavior. Under these conditions, 
the hyper-mobility of the ST DBP KO mice and the depressed mobility of the ST DBP 
WT mice were stabilized between the two extremes, indicating the possibility that DHA 
supplementation stabilized mood in these mice. In addition, the anti-depressive effects of 
DHA are stronger in female mice, while the anti-manic effects are stronger in male mice. 
However, a study using a much larger cohort of mice is necessary to confirm these 
conclusions. Unfortunately, we did not test NST DBP KO mice, which showed a 
depressive-like phenotype in our previous study. However, our ST WT mice, which also 
showed a depressive-like phenotype, demonstrate an anti-depressive response, especially 
for female mice, when on a high DHA diet. Perhaps DHA would have an anti-depressive 
affect on NST DBP KO mice as well, but future studies are needed to extrapolate to these 
mice. 
From our microarray data, we were able to generate lists of numerous genes that 
were significantly changed in at least two out of three microarray experiments comparing 
ST DBP KO mice on a high verses low DHA diet. Among the genes changed by DHA 
treatment in the PFC of male mice were FOS, NDUFAB1, and COL16A1. These genes 
were changes in the opposite direction as reported for the postmortem brain of humans 
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with bipolar disorder. Similarly, the genes MBP, NEFH, GSN, PPP1R1B, CLDN11, 
MOG, QDPR, SYT2 MOBP, and PLP1 were changed in the opposite direction in the 
PFC of the female ST DBP KO mice on the high DHA diet as compared to the 
postmortem brain of humans with bipolar disorder. This indicates a potential reversal by 
DHA supplementation of gene expression levels abnormally altered in bipolar patients. In 
addition, Ingenuity analysis showed that the key functions in which a vast number of 
changed genes are involved include neurological disease and nervous system 
development for males and neurological disease, nervous system development, cell death, 
behavior, and genetic and psychological disorders for females, all of which are associated 
with bipolar disorder. A diet high in DHA may be causing the observed stabilization of 
behavior in our mice by affecting the expression of these genes.  
 Though upregulation of the AA cascade has been strongly linked to bipolar 
disorder, and has been shown to serve as a target of currently prescribed mood stabilizers 
(Figure 1), our genetic results did not show changes in genes in this cascade. However, 
DRD2, the gene producing the dopamine D2 receptor, was upregulated in female ST 
DBP KO mice on the high DHA diet compared to their counterparts on the low DHA 
diet. The AA cascade has been linked to this receptor; however, more studies need to be 
performed to confirm this in vivo [29]. D2 is a G-protein coupled receptor that is 
activated by dopamine, and through downstream effects, exerts largely inhibitory 
responses in neurons. D2 receptors can be postsynaptic or can also serve as presynaptic 
autoreceptors. As elevated extracellular dopamine levels have been correlated with manic 
episodes [206], perhaps elevated DHA levels induce upregulation of the D2 receptor, in 
effect reducing dopamine release. Interestingly, the DRD1A gene, which encodes the D1 
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receptor A subunit, is also upregulated in the PFC of the female mice on the high DHA 
diet. A positron emission tomography study on bipolar patients in the euthymic, 
depressed, and manic states showed that D1-receptor binding is significantly decreased in 
the frontal cortex of these patients, regardless of mood, compared to control [207]. In this 
regard one might speculate that DHA is restoring the expression of this receptor to a 
more normal level. The upregulation of these two receptors may underlie the fine-tuning 
of dopaminergic signaling in the PFC of the female mice on the high diet, leading to 
modulated mood. It would be interesting to determine if dopamine signaling is indeed 
increased in the brains of our ST DBP KO mice, and if DHA can decrease this release. It 
would also be informative to perform experiments similar to those performed by Rao et 
al. and determine if AA levels in the PFC of NST and ST DBP KO mice on the high 
DHA diet are modulated compared to mice on the low DHA diet [5]. Using radiolabeled 
fatty acid and quantitative autoradiographic analysis, we could determine AA and DHA 
turnover rates in the PFC of our mice, indicating whether or not the AA cascade plays a 
role in the behavioral and genetic expression outcomes. 
 Of further interest, numerous genes associated with myelin are increased in the 
female ST DBP KO mice on the diet high in DHA compared to those on the low DHA 
diet. Many of these changed genes were increased in the PFC region of the females on 
the high diet relative to the females on the low diet. Interestingly, reduced myelin staining 
and expression of oligodendrocyte-related genes were reported in the postmortem brain 
of patients with bipolar disorder [208]. Neuroimaging and neuropathological studies have 
shown reduced oligodendrocytes in PFC white matter and alterations in the tracts that 
connect the PFC to subcortical regions known to be involved in emotion [209]. Kato 
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suggests that this may be due to a vulnerability to stress and death of some neurons, an 
hypothesis supported by the reduced density of neurons in brain areas such as the PFC, 
anterior cingulated gyrus, and hippocampus of bipolar patients [13]. To further test this, 
immunohistochemistry could be performed on brain slices from DBP KO mice, staining 
for myelin associated genes, to assess a deficit in myelin in the PFC or other brain 
regions of these mice compared to WT mice. 
A potential point of concern for our male gene expression data is that there is no 
overlap with those female genes that changed by criterion. However, many of the 
biological and canonical pathways for these genes did overlap. Perhaps the affect of DHA 
reaches the same outcomes for male and female mice, while targeting different genes to 
reach these same results. As we had expected, many of the genes changed in expression 
for males are involved in neurological disease, neuron development, and cell growth. Of 
further interest, many of the candidate genes are involved in gene expression regulation 
and cell signaling, specifically Reelin signaling. In conjunction with this finding, a study 
on rat brains showed significant alterations in the mRNA levels of Reelin associated 
genes when the rats were treated with mood stabilizers [210]. Of particular intrigue, 
Reelin expression is regulated by dopamine responsive promoters [201]. Bipolar patients 
indeed have alerations in dopamine signaling, which thus could affect promoter 
methylation or acetylation. This could lead to altered expression of genes including those 
involved in Reelin signaling, affecting neuronal outgrowth, axonal branching, and 
synaptogenesis [211]. Genes serving as transcription factors, such as SFPQ were also 
increased in the PFC of male mice, which could further alter gene expression. Based on 
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these findings, perhaps DHA is affecting more upstream proteins in the female mice and 
downstream substrates in the male mice. 
Another interesting aspect of our study is that our mice were stressed via acute 
and chronic stressors. Indeed, mood and anxiety disorders are often co-morbid in humans 
[212] and several of the genes in our lists, especially for male mice, have been linked in 
humans to anxiety and stress, such as CDKN1C, PRKAR2B, CRYAB, FOXO3A, 
DRD1A, FOS NDUFAB1, ARF3, HSPA4, and UBE2D2. Studies on human volunteers 
have found reduced plasma adrenaline and noradrenaline levels after omega-3 fatty acid 
supplementation containing DHA and EPA for two months compared to placebo-treated 
controls [213]. Such findings suggest that omega-3 fatty acid supplementation may 
decrease the activation of the hypothalamic-pituitary-adrenal axis, which is related to 
anxiolytic effects [212]. It would be interesting in future studies to test ST DBP KO mice 
on a high verses low DHA diet on anxiety-related behavioral tests such as elevated plus 
maze, radial arm maze, and social interaction tests, to determine if DHA is able to lower 
anxiety-related outcomes for these tests as well.  
 In addition to the behavioral and genetic data, we were able to show that ST DBP 
KO mice on a high DHA diet drank significantly less total alcohol over a two week and 
four week period. Interestingly, when the acute stressor was added on day 21, the 
significance between groups was lost. Perhaps DHA works at suppressing alcohol intake 
up to a certain level of stress, but during extreme, acute stress, can no longer do so. Tests 
were also performed on a rat model of alcoholism and produced a dose-dependent trend 
for DHA treatment, with significant difference reached between high and low DHA diets. 
This not only supports our alcohol data for our mouse model, but also suggests that DHA 
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could be of benefit for suppressing alcohol consumption even without co-morbid bipolar 
disorder. It would be informative to provide a cohort of ST and NST DBP KO mice a 
drug that could serve as a positive control, such as disulfiram, which is an FDA approved 
alcohol suppressant [214]. We would compare alcohol consumption in these mice to mice 
without disulfiram but with DHA in the diet and to a negative control that was not given 
disulfiram or DHA. This would allow our laboratory to determine if DHA could be as 
effective as a presently prescribed medication for suppressing alcohol consumption, 
without causing the adverse side-effects sometimes induced by this medication.  
For our studies, we wanted to model the low omega-3 fatty acids diets of the 
Western hemisphere verses the high omega-3 fatty acids diets of countries such as Japan, 
with individuals in Japan eating eight times the amount of omega-3 fatty acids ingested 
by the average American in the US per year [215], so we used diets with very low or very 
high DHA levels. It may also be beneficial to study the effects of a control diet on our 
mice, as was given to the alcohol-preferring (P) rats. This would provide dose-dependent 
information for a DHA effect, as well as a standard by which to compare the extreme 
groups. Moreover, it would be beneficial to offer diets consisting of increasing levels of 
DHA, as the high diet provided ~0.035 g of omega-3 fatty acid to the mice per day, 
which is the equivalent of 90 g daily of omega-3 fatty acid to an average-size human 
adult. Since this is quite an excess to the recommended dose of 500mg/day for heart 
patients [216], testing cohorts of mice with increasing amounts of DHA in their diet 
would be informative, as the optimal therapeutic amount could be determined. 
Another potential addition for our studies may be the inclusion of the omega-3 
fatty acid EPA in the high DHA diet. Like DHA, EPA levels are reduced in the 
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postmortem brains of bipolar patients [217]. In addition, EPA directly antagonizes 
membrane AA and reduces PGE2 synthesis, thereby balancing immune and inflammatory 
function [6] (Figure 2). In fact, preliminary studies have shown beneficial effects of 
increased EPA in the diet for patients with psychiatric disorders [24, 26]. 
 Once a reasonable, therapeutic dose of DHA supplement per day is determined 
for DBP KO mice (and potentially with EPA as well), and the results have been 
successfully replicated using large cohorts of animals, clinical trials could be considered 
on patients with bipolar disorder. Indeed, studies from other groups have reported 
beneficial effects of omega-3 fatty acid supplements for bipolar patients [60, 218]. 
 One specific population that could benefit from DHA supplements are adolescents 
at high risk of developing bipolar disorder due to genetic and environmental factors. 
Indeed, a study by Amminger et al. gave adolescents at ultra-high risk for psychosis 480 
mg of DHA a day, in addition to other PUFAs, or placebo for 12 weeks [24]. They 
showed that adolescents taking the DHA supplements had a significantly lower number 
of transitions to psychotic disorder than their placebo-treated counterparts (5% transition 
compared to 28%). A similar study could be performed on adolescents at high risk for 
bipolar disorder to see if DHA could prevent the transition to the disease. DHA would be 
an excellent candidate for these individuals, as it does not have clinically relevant adverse 
side-effects, and the use of medications for bipolar disorder is controversial for at-risk 
teens [15]. 
 Another population of individuals who could greatly benefit from a healthy 
mood-stabilizing supplement is pregnant women with bipolar disorder. This disorder 
usually develops in late adolescence and early adulthood, which places its onset during 
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the prime reproductive years for women. A study performed on over 11,000 pregnant 
women found that, unlike mood stabilizing drugs that are currently prescribed for bipolar 
patients, consumption of food high in omega-3 fatty acids did not cause harmful effects 
to their offspring [199]. They discovered that maternal seafood consumption of more than 
340 g per week provided beneficial effects on child development, whereas a diet 
consisting of less than 340 g of seafood per week did not protect children from adverse 
outcomes, such as suboptimum scores for prosocial behavior, communication, fine motor, 
and social development. They concluded that the risks from the loss of omega-3 fatty 
acids were greater than the risks of potential exposure to trace contaminants in 340 g or 
more of seafood eaten on a weekly basis. In addition, maternal DHA status declines in 
pregnant women after the second trimester [219]. Studies in our DBP KO mice could be 
performed where pregnant NST and ST DBP KO mice are given a diet high in DHA and 
developmental, behavioral, and genetic effects would be compared to NST and ST DBP 
KO pregnant mice given a low DHA or control diet. Another group of pregnant KO mice 
would be given a control diet with lithium to serve as a positive control of mood 
stabilization and potential birth defects [16]. Once confirmed in rodents, clinical trials 
could be performed where DHA supplements were given to pregnant patients with 
bipolar disorder to see if mood was stabilized, without harming the fetus. 
 Based on our studies, a final cohort that may benefit from DHA supplements is 
the 40-60% of bipolar disorder patients who have co-morbid alcoholism [220]. Animal 
studies have shown that prolonged alcohol consumption leads to a reduction in brain 
DHA levels [221-222], and our studies on two different rodent models showed a 
significant decrease in alcohol consumption with DHA diet supplementation. Current 
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drugs prescribed as alcohol suppressants have adverse side-effects [214], and DHA could 
provide a healthier supplement for these individuals, without causing negative side-
effects. Our evidence is preliminary, however, and much further study needs to be 
accomplished before it can be translated to humans. 
 Overall, our studies with DBP KO mice reveal the potential of the DBP gene as a 
biomarker for bipolar disorder and support the DBP KO mice, under non-stressed and 
stressed conditions, as a strong candidate model of the disorder. This model is limited, 
however, since bipolar disorder is likely caused by a compilation of mutated genes. 
Nevertheless, the DBP KO mouse serves as a good model in which to test bipolar 
disorder mechanisms and potential mechanisms of drug and supplement treatments. 
Indeed, based on our studies, in addition to the vast number of previous studies 
performed by other laboratories, supplements of the omega-3 fatty acid, DHA, may have 
mood stabilizing capabilities and this potential warrants further research. 
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